



HEDIS[®] MY 2026

Quick Reference Guide

For more information, visit [ncqa.org](https://www.ncqa.org)





HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). The HEDIS measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in these materials and may rescind or alter these materials at any time. Users of the HEDIS measures and specifications shall not have the right to alter, enhance, or otherwise modify the HEDIS measures and specifications, and shall not disassemble, recompile, or reverse engineer the HEDIS measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modification for an internal non-commercial purpose may do so without obtaining any approval from NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use, or any external reproduction, distribution, or publication must be approved by NCQA and are subject to a license at the discretion of NCQA.

For a complete list of codes and the most recent HEDIS measurements, standards, and information about changes the NCQA made to the technical specifications, such as changing the terminology from “member” to “person,” please visit the NCQA website at [ncqa.org](https://www.ncqa.org), or see the HEDIS value sets. Only subsets of the NCQA-approved codes are listed in this document. This list is not exhaustive. This information is based on technical specification released in August 2025. An addendum document will be available after the final technical specifications are released in spring 2026.

HEDIS[®] MY 2026

Quick Reference Guide

Updated to reflect NCQA HEDIS MY 2026 Technical Specifications

Iowa Total Care strives to provide quality healthcare to our membership as measured through HEDIS quality metrics. We created the HEDIS MY 2026 Quick Reference Guide to help you increase your practice's HEDIS rates and address care opportunities for your patients. Please always follow the state and/or Centers for Medicare and Medicaid Services (CMS) billing guidance and ensure the HEDIS codes are covered prior to submission. Measurement period 2026 is defined as Jan. 1, 2026 through Dec. 31, 2026.



What is HEDIS[®]?

Healthcare Effectiveness Data and Information Set (HEDIS) is a set of standardized performance measures developed by the National Committee for Quality Assurance (NCQA) to objectively measure, report, and compare quality across health plans. NCQA develops HEDIS measures through a committee represented by purchasers, consumers, health plans, healthcare providers, and policy makers.

▶ What are the scores used for?

As state and federal governments move toward a quality-driven healthcare industry, HEDIS rates are becoming more important for both health plans and individual providers. State purchasers of healthcare use aggregated HEDIS rates to evaluate health insurance companies' efforts to improve preventive health outreach for persons.

Physician-specific scores are also used to measure your practice's preventive care efforts. Your practice's HEDIS score determines your rates for physician incentive programs that pay you an increased premium — for example, Pay for Performance or Quality Bonus Funds.

▶ How are rates calculated?

HEDIS rates are collected in various ways: administrative data, hybrid (medical record review data), and electronic clinical data systems (ECDS). *Administrative* data consists of claim or encounter data submitted to the health plan. *Hybrid* data consists of both administrative data and a sample of medical record data. Hybrid data requires review of a random sample of person medical records to abstract data for services rendered but not reported to the health plan through claims/encounter data. Accurate and timely claim/encounter data reduces the need for medical record review. If services are not billed or billed inaccurately, they are not included in the calculation.

(continued)



Transition to ECDS-Only Reporting

Over the last several years, NCQA has added the option to report the ECDS reporting standard for several existing HEDIS measures alongside traditional HEDIS reporting. This allows health plans to assess their ECDS reporting capabilities and represents a step forward in adapting HEDIS to accommodate the expansive information available in electronic clinical datasets used for patient care and quality improvement.

Based on these results, NCQA has announced the transition of several measures to ECDS-only. The major reporting change to be aware of is that the traditional hybrid measure (LSC) that transitions to ECDS-only will no longer use the annual chart retrieval process to demonstrate compliance. All compliance from medical records must be processed through prospective supplemental data. The data sources for ECDS are Electronic Health Records, Health Information Exchanges, Case Management Systems, and Administrative Claims. For more information on ECDS and the data allowed for compliance, please visit ncqa.org/hedis/the-future-of-hedis/hedis-electronic-clinical-data-system-ecds-reporting/.

ECDS Measures Effective for MY 2026

Adult Immunization Status (AIS-E)	(MCD*)**
Blood Pressure Control for Patients With Diabetes (BPD-E)	(MCD)
Blood Pressure Control for Patients With Hypertension (BPC-E)	(MCD*)
Breast Cancer Screening (BCS-E)	(MCD*)**
Cervical Cancer Screening (CCS-E)	(MCD*)**
Childhood Immunization Status (CIS-E)	(MCD*)**
Colorectal Cancer Screening (COL-E)	(MCD*)**
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)	(MCD*)
Documented Assessment After Mammogram (DBM-E)	(MCD)
Follow-Up After Abnormal Mammogram Assessment (FMA-E)	(MCD)
Follow-Up After Acute and Urgent Care Visits for Asthma (AAF-E)	(MCD)
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	(MCD*)**
Immunizations for Adolescents (IMA-E)	(MCD*)**
Lead Screening in Children (LSC-E)	(MCD)
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	(MCD*)**
Postpartum Depression Screening and Follow-Up (PDS-E)	(MCD)
Prenatal Depression Screening and Follow-Up (PND-E)	(MCD)
Prenatal Immunization Status (PRS-E)	(MCD*)**
Statin Therapy for Patients With Cardiovascular Disease (SPC-E)	(MCD)
Statin Therapy for Patients With Diabetes (SPD-E)	(MCD)
Social Need Screening and Intervention (SNS-E)	(MCD)
Tobacco Use Screening and Cessation Intervention (TSC-E)	(MCD)
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)	(MCD)

*Impact to Health Plan Rating/MA Stars/QRS Stars information as of MY 2025. MY 2026 information is pending.

**Required to be reported for Medicare and Medicaid plans with Accreditation. Information as of MY 2025. MY 2026 information is pending.

(continued)



How can I improve my HEDIS® scores?

- ✓ Conduct preventive care visits annually and ensure your patients are up to date with their recommended screenings (i.e., mammograms, colonoscopies, etc.).
- ✓ Ensure that all claim/encounter data for each and every service rendered is submitted in an accurate and timely manner.
- ✓ Include Current Procedural Terminology (CPT) II codes to provide additional details and reduce medical record requests.
- ✓ Make sure that chart documentation reflects all services billed.
- ✓ Bill (or report by encounter submission) for all delivered services, regardless of contract status.
- ✓ Respond timely to medical records requests.
- ✓ Submit supplemental data throughout the measurement period.
- ✓ Early engagement with pharmacy adherence is key — once a person loses days on a prescription, those days cannot be recovered.
- ✓ Speak with the persons about any barriers to adherence.
- ✓ Consider utilizing RxEffect — a free online portal for our network providers that will prioritize your high-risk patients more efficiently. This will save on resources, as it lists your patients at highest risk for non-adherence.
- ✓ If you have any questions regarding pharmacy and person barriers, please reach out to your local Provider Relations Representative for assistance.
- ✓ Speak with your patients about the availability of a transportation benefit (if applicable) to assist with access to care.
- ✓ Ensure that patients are aware of the option for mail-order prescription refills.
- ✓ Remember that you are now able to prescribe 100 days' supply of medications for both retail and mail-order.



Updates to HEDIS® Measures

This guide has been updated with information from the release of the HEDIS 2026 Volume 2 Technical Specifications by NCQA and is subject to change.

► **New Measures MY 2026:**

- Blood Pressure Control for Patients With Diabetes (BPD-E)
- Follow-Up After Acute and Urgent Care Visits for Asthma (AAF-E)
- Tobacco Use Screening and Cessation Intervention (TSC-E)

(continued)

► **Retired Measures MY 2026:**

- Asthma Medication Ratio (AMR)
- Lead Screening in Children (LSC)*
- Statin Therapy for Patients With Cardiovascular Disease (SPC)*
- Statin Therapy for Patients With Diabetes (SPD)*
- Medical Assistance With Smoking and Tobacco Use Cessation (MSC)

**Only the LSC-E, SPD-E and SPC-E will be reported.*

► **Transitioned Measures MY 2026:**

- Lead Screening in Children (LSC-E)
- Statin Therapy for Patients With Cardiovascular Disease (SPC-E)
- Statin Therapy for Patients With Diabetes (SPD-E)



Availity














Clinical Quality Validation (CQV) is a time-saving application within Availity® Essentials that allows providers to quickly address and submit documentation for open Quality Care gaps, and is a source of submission for Pay for Performance (P4P)/Partnership 4 Quality (P4Q) programs. With an integrated workflow, pre-populated forms, document upload, and status tracking, CQV is entirely digital from start to finish. Providers can electronically document their patient's care and assessments to close HEDIS quality care gaps for health plan persons using CQV.

- ✓ The provider's office must be registered with Availity (**availity.com**) to receive and respond to quality care gaps electronically.
- ✓ Availity administrators must ensure that the roles to access CQV are assigned to the proper users.
Tip: Locate the administrator for the organization in the Essentials menu bar. Click *[Your Name's] Account | My Account | Organization(s) | Open My Administrators*.
- ✓ Trainings and step-by-step documentation on how to navigate Availity's CQV portal can be found within Availity Essentials under the Help & Training tab.

The Availity CQV portal can be used in place of mailing and faxing medical records, relieving the administrative burden on the provider's office.

CONTENTS

ADULT HEALTH








	(AAP) Adults' Access to Preventive/Ambulatory Health Services	11
	(AIS-E) Adult Immunization Status	12
	(BPC-E) Blood Pressure Control for Patients With Hypertension	12
	(BPD) Blood Pressure Control for Patients With Diabetes.....	13
	(BPD-E) Blood Pressure Control for Patients With Diabetes	14
	(CBP) Controlling High Blood Pressure	15
	(COL-E) Colorectal Cancer Screening	16
	(EED) Eye Exam for Patients With Diabetes.....	17
	(GSD) Glycemic Status Assessment for Patients With Diabetes	18
	(KED) Kidney Health Evaluation for Patients With Diabetes	19
	(PCE) Pharmacotherapy Management of COPD Exacerbation.....	20
	(PCR) Plan All-Cause Readmissions.....	21
	(SPC-E) Statin Therapy for Patients With Cardiovascular Disease	22

PHARMACY MEASURES









	(SPD-E) Statin Therapy for Patients With Diabetes	24
---	---	-----------

CONTENTS

WOMEN'S HEALTH








	(BCS-E) Breast Cancer Screening	25
	(CCS-E) Cervical Cancer Screening	25
	(CHL) Chlamydia Screening.....	26
	(DBM-E) Documented Assessment After Mammogram	27
	(FMA-E) Follow-Up After Abnormal Mammogram Assessment.....	29
	(PPC) Prenatal and Postpartum Care	31
	(PRS-E) Prenatal Immunization Status.....	32

PEDIATRIC HEALTH


	(CIS-E) Childhood Immunization Status	33
	(IMA-E) Immunizations for Adolescents	34
	(LSC-E) Lead Screening in Children	35
	(OED) Oral Evaluation, Dental Services.....	35
	(TFC) Topical Fluoride for Children	36
	(W30) Well-Child Visits in the First 30 Months of Life	36
	(WCC) Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents.....	37
	(WCV) Child and Adolescent Well-Care Visits.....	38

CONTENTS









GENERAL HEALTH

	(AAB) Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis	39
	(AAF-E) Follow-Up After Acute and Urgent Care Visits for Asthma.....	40
	(CWP) Appropriate Testing for Pharyngitis.....	41
	(LBP) Use of Imaging Studies for Low Back Pain.....	42
	(SNS-E) Social Needs Screening and Intervention	43
	(TSC-E) Tobacco Use Screening and Cessation Intervention.....	47
	(URI) Appropriate Treatment for Upper Respiratory Infection.....	48













SOCIAL DETERMINANTS OF HEALTH

	(SDOH) Social Determinants of Health	49
--	--	-----------

BEHAVIORAL HEALTH

	(ADD-E) Follow-up Care for Children Prescribed ADHD Medication.....	50
	(APM-E) Metabolic Monitoring for Children and Adolescents on Antipsychotics.....	52
	(APP) Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics.....	53
	(ASF-E) Unhealthy Alcohol Use Screening and Follow-Up.....	53
	(COU) Risk of Continued Opioid Use.....	55
	(DSF-E) Depression Screening and Follow-Up for Adolescents and Adults	56
	(FUA) Follow-Up After Emergency Department Visit for Substance Use Disorder (SUD)	58
	(FUH) Follow-Up After Hospitalization for Mental Illness	61

CONTENTS

	(FUI) Follow-Up After High-Intensity Care for Substance Use Disorder (SUD)	63
	(FUM) Follow-Up After Emergency Department Visit for Mental Illness.....	65
	(HDO) Use of Opioids at High Dosage.....	67
	(IET) Initiation and Engagement of Substance Use Disorder (SUD) Treatment	71
	(PDS-E) Postpartum Depression Screening and Follow-Up.....	73
	(PND-E) Prenatal Depression Screening	76
	(POD) Pharmacotherapy for Opioid Use Disorder	78
	(SAA) Adherence to Antipsychotic Medications for Individuals With Schizophrenia	79
	(SMC) Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia.....	80
	(SMD) Diabetes Monitoring for People With Diabetes and Schizophrenia.....	81
	(SSD) Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	82
	(UOP) Use of Opioids From Multiple Providers	83

ADULT HEALTH

Call To Action: Please refer to the provider portal to find a complete list of person care gaps as applicable for the measures in this document.



(AAP) Adults' Access to Preventive/Ambulatory Health Services

Measure evaluates the percentage of persons 20 years of age and older who had an ambulatory or preventive care visit during the measurement period. Commercial persons who had an ambulatory or preventive care visit during the measurement period or the two years prior to the measurement. Services that count include outpatient evaluation and management (E&M) visits, consultations, assisted living/home care oversight, preventive medicine, and counseling.



Tips

- Synchronous telehealth visits, asynchronous telehealth visits (e-visits and virtual check-ins), or telephone visits are acceptable.
- Help or schedule person's appointments for preventive care visits.
- Document the date and the type of visit.
- Submit the applicable codes.

CPT*	HCPCS*	ICD-10*
98966–98972, 99201–99205, 99211–99215, 99241–99245, 99341–99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99429, 92002, 92004, 92012, 92014, 99304–99310, 99315, 99316, 99318, 99324–99328, 99334–99337, 99421–99423, 99441–99444, 99457, 99458, 99483	G0071, G0402, G0438, G0439, G0463, G2010, G2012, G2063, G2251, G2252, S0620, S0621, S2250, T1015	Z00.00, Z00.01, Z00.121, Z00.129, Z00.3, Z00.5, Z00.8, Z02.0, Z02.1, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9, Z76.1, Z76.2

*Codes subject to change.





(AIS-E) Adult Immunization Status

Measure evaluates the percentage of persons 19 years of age and older who are up to date on recommended routine vaccines for influenza, tetanus, and diphtheria (Td) or tetanus, diphtheria, and acellular pertussis (Tdap), zoster, pneumococcal, hepatitis B, and coronavirus disease 2019 (COVID-19).



Tips

- Schedule appointments within immunization timeframes.
- Discuss the importance of vaccinations during person appointments.
- Include immunization history from all sources in the person’s medical record.
- Use electronic medical record (EMR) system to set reminders flags.

Description	Codes*
Adult Hepatitis B Vaccine Procedure	CPT: 90697, 90723, 90739, 90740, 90743, 90744, 90746–90759
Adult Influenza Vaccine Procedure	CPT: 90653, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756
Adult Pneumococcal Vaccine Procedure	CPT: 90670, 90671, 90677, 90684, 90732 HCPCS: G0009
COVID-19 Vaccine Procedure	CPT: 91304, 91320, 91322
Td Vaccine Procedure	CPT: 90714
Tdap Vaccine Procedure	CPT: 90715
Herpes Zoster Vaccine Procedure	CPT: 90750

*Codes subject to change.



(BPC-E) Blood Pressure Control for Patients With Hypertension

Measure evaluates the percentage of persons 18 to 85 years of age during the measurement period who had a diagnosis of hypertension (HTN) and whose most recent blood pressure (BP) was <140/90 mm Hg during the measurement period.

The HTN diagnosis or HTN+ med can occur anytime between Jan. 1 of the prior year and Jun. 30 of the measurement period.

*Note: For a person to be included in measure, the person must have had at least two medical visits on two different dates of service with a diagnosis of HTN, **OR** one medical visit with a diagnosis of HTN and a dispensed antihypertension medication.*



Tips

- Collect BP reading via any telehealth visit (does not require a remote monitoring device to be the source).
- Retake BP readings if the reading is = or >140/90 mm Hg.
- Help persons schedule their hypertension follow-up appointments.
- Educate persons on what a controlled BP means.
- Talk with persons about taking their own BP via a digital device.
- If a person uses a digital device and reports the blood pressure reading(s), ensure the reading(s) are captured in the person’s EMR.
- Submit applicable codes.



(BPC-E) Blood Pressure Control for Patients With Hypertension *(continued)*

Description	Codes*
Diastolic Blood Pressure	CPT II: 3078F, 3079F, 3080F
Diastolic Less Than 90	CPT II: 3078F, 3079F
Systolic and Diastolic Result	CPT: 3074F, 3075F, 3077F, 3078F, 3079F, 3080F
Systolic Blood Pressure	CPT: 3074F, 3075F, 3077F
Systolic Less Than 140	CPT: 3074F, 3075F
Hypertension/Essential Hypertension	ICD-10-CM: I10
Exclusion: Encounter for Palliative Care	ICD-10-CM: Z51.5

*Codes subject to change.



(BPD) Blood Pressure Control for Patients With Diabetes

Measure evaluates the percentage of persons 18 to 75 years of age with diabetes (type 1 or 2) whose BP was adequately controlled (<140/90 mm Hg) during the measurement period.

Persons are identified by at least two diabetes diagnoses during measurement period or PY, or at least one diabetes diagnosis and at least one diabetes medication dispensing event.

Tips

- For self-reported BP readings, the person is required to utilize a digital device to record their BP measurement. Manual BP readings are not acceptable.
- Check BP on both arms and record the lowest systolic and diastolic readings.
- If the initial BP reading is >140 systolic or >90 diastolic on first measurement, retake BP readings after patient rests quietly for five minutes. Remember to record both the initial and second BP readings.
- Never round up BP readings.
- Use correct cuff size on bare arm.
- The most recent BP reading during the measurement period is used.
- Persons should rest quietly for at least five minutes before the first BP is taken.
- The last BP reading taken during the measurement period is used.
- Submit applicable codes.

Description	Codes*
Palliative Care	HCPCS: G9054
Systolic Greater Than/Equal to 140	CPT II: 3077F
Systolic 130–139	CPT II: 3075F
Systolic Less Than 130	CPT II: 3074F
Diastolic 80–89	CPT II: 3079F
Diastolic Greater Than/Equal to 90	CPT II: 3080F
Diastolic Less Than 80	CPT II: 3078F

*Codes subject to change.





(BPD-E) Blood Pressure Control for Patients With Diabetes

This is a first-year measure.

Measure evaluates the percentage of persons 18 to 75 years of age with diabetes (type 1 or 2) whose most recent BP was <140/90 mm Hg during the measurement period.

Persons are identified by a diabetes diagnosis.

Either of the following meets criteria:

- ✓ **Claim/encounter data.** At least two diagnoses of diabetes (Diabetes Value Set — Do not include laboratory claims [claims with POS code 81]) on different dates of service during the measurement period or the year prior to the measurement period.
- ✓ **Pharmacy data.** At least one diagnosis of diabetes (Diabetes Value Set — Do not include laboratory claims [claims with POS code 81]) and at least one diabetes medication dispensing event of insulin or a hypoglycemic/antihyperglycemic medication (Diabetes Medications List) during the measurement period or the year prior to the measurement period.



Tips

- For self-reported BP readings, the person is required to utilize a digital device to record their BP measurement. Manual BP readings are not acceptable.
- Check BP on both arms and record the lowest systolic and diastolic readings.
- If the initial BP reading is >140 systolic or >90 diastolic on first measurement, retake BP readings after patient rests quietly for five minutes. Remember to record both the initial and second BP readings.
- Never round up BP readings.
- Use correct cuff size on bare arm.
- The most recent BP reading during the measurement period is used.
- Persons should rest quietly for at least five minutes before the first BP is taken.
- The last BP reading taken during the measurement period is used.
- If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

If the most recent BP was identified based on a CPT Category II code (Systolic and Diastolic Result Value Set), use the following to determine compliance:

Description	Codes*
Systolic 130–139	CPT II: 3075F
Diastolic 80-89	CPT II: 3079F
Diastolic Less Than 80	CPT II: 3078F

*Codes subject to change.





(CBP) Controlling High Blood Pressure

Measure evaluates the percentage of persons 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm Hg) during the measurement period.

Persons are identified by at least two visits with different dates of service with a diagnosis of hypertension on or between 1/1/PY–6/30/MY.



Tips

- For self-reported BP readings, the person is required to utilize a digital device to record their BP measurement. Manual BP readings are not acceptable.
- Check BP on both arms and record the lowest systolic and diastolic readings.
- If the initial BP reading is >140 systolic or >90 diastolic on first measurement, retake BP readings after patient rests quietly for five minutes. Remember to record both the initial and second BP readings.
- Never round up BP readings.
- Use correct cuff size on bare arm.
- The most recent BP reading during the measurement period is used.
- Persons should rest quietly for at least five minutes before the first BP is taken.
- The last BP reading taken during the measurement period is used.
- Submit applicable codes.

Note: When submitting CPT II codes, report both systolic and diastolic to complete blood pressure reading.

Description	Codes*
Systolic Greater Than/Equal to 140	CPT II: 3077F
Systolic Less than 140	CPT II: 3074F, 3075F
Diastolic Greater Than/Equal to 90	CPT II: 3080F
Diastolic 80–89	CPT II: 3079F
Diastolic Less Than 80	CPT II: 3078F

*Codes subject to change.





(COL-E) Colorectal Cancer Screening

Measure evaluates the percentage of persons 45 to 75 years of age who had an appropriate screening for colorectal cancer during the measurement period.



Tips

- Educate persons on proper sample collection when distributing fecal immunochemical test (FIT) or fecal occult blood test (FOBT) testing kits.
- Complete and document all screenings for patients.
- Educate persons on the importance of colorectal cancer screenings for early detection and the options available to complete their screening.
- Talk with persons about using the home screenings for their colorectal cancer screening.
- Help persons schedule their colonoscopy screening appointments.
- Submit applicable codes.

Description	Codes*
Colonoscopy (within past 10 years)	CPT: 44388–44392, 44394, 44401–44408, 45378–45382, 45384–45386, 45388–45393, 45398 HCPCS: G0105, G0121
CT Colonography (within past five years)	CPT: 74261–74263
sDNA FIT Lab Test (within past three years)	CPT: 0464U, 81528
Flexible Sigmoidoscopy (within past five years)	CPT: 45330–45335, 45337–45338, 45340–45342, 45346–45347, 45349, 45350 HCPCS: G0104
FOBT Lab Test (within measurement period)	CPT: 82270, 82274 HCPCS: G0328
Colorectal Cancer	ICD-10: C18.0–C18.9, C19, C20, C21.2, C21.8, C78.5, Z85.038, Z85.048
Palliative Care	HCPCS: G9054
Total Colectomy	CPT: 44150–44153, 44155–44158, 44210–44212

*Codes subject to change.





(EED) Eye Exam for Patients With Diabetes

Measure evaluates the percentage of persons 18 to 75 years of age with diabetes (type 1 or 2) who had a retinal eye exam during the measurement period.

Persons are identified by at least two diabetes diagnoses during measurement period or PY, or at least one diabetes diagnosis and at least one diabetes medication dispensing event.

Include the diagnosis of uncomplicated diabetes diagnosis on all claims as applicable.



Tips

- Refer all diabetic persons to an acceptable eye care professional (optometrist or ophthalmologist) annually for a dilated or retinal diabetic eye exam.
- Educate persons on the eye damage that could be caused by their diabetes.
- Help persons to schedule their annual diabetic eye exam appointments.
- Evidence of a result (whether retinopathy is found or not) must be present.
- Submit applicable codes.

Description	Codes*
Retinal Eye Exam (Billed by an Eye Care Professional)	CPT: 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92137, 92201–92205, 92230, 92235, 92250, 99213–99215, 99242–99245 HCPCS: S0620, S0621, S3000
Retinal Imaging	CPT: 92227, 92228
Autonomous Eye Exam	CPT: 92229 LOINC: 105914-6 with a result
Interactive Outpatient Encounter	CPT: 98970–98972, 99421–99423, 99457 HCPCS: G0071, G2010, G2012
Unilateral Eye Enucleation With a Bilateral Modifier	CPT: 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114 CPT Modifier: 50
Eye Exam With Retinopathy	CPT II: 2022F, 2024F, 2026F
Eye Exam Without Retinopathy	CPT II: 2023F, 2026F, 2033F
Diabetic Retinal Screening Negative in Prior Year	CPT II: 3072F

*Codes subject to change.





(GSD) Glycemic Status Assessment for Patients With Diabetes

Measure evaluates the percentage of persons 18 to 75 years of age with diabetes (type 1 or 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement period:

- ✓ Glycemic Status <8.0%
- ✓ Glycemic Status >9.0%

Persons are identified by at least two diabetes diagnoses during measurement period or PY or at least one diabetes diagnosis and at least one diabetes medication dispensing event.

Tips

- If the glycemic status is >9.0%, re-test after implementing appropriate treatment.
- POC testing is acceptable with appropriate coding and documentation with date of service and value.
- Person-reported A1c/glucose results are acceptable if documented in chart with test date and value.
- Conduct a diabetic visit with diabetic patients at least once per year.
- Document all A1c lab values with dates for diabetic persons.
- Provide education to persons regarding the need to monitor and manage their blood sugars (HgA1c).
- Assist persons if needed to schedule lab visits for regular A1c testing to include transportation assistance.
- Submit applicable codes.

Note: A person who was previously compliant can become non-compliant with a more recent result.

Description	Codes*
HbA1c Lab Test	CPT: 83036, 83037
HbA1c Level Less Than 7	CPT II: 3044F
HbA1c Level Greater Than/Equal to 7 and Less than 8	CPT II: 3051F
HbA1c Level Greater Than/Equal to 8 and Less Than/Equal to 9	CPT II: 3052F
HbA1c Greater Than 9.0	CPT II: 3046F

*Codes subject to change.

*Note: Do **not** include a modifier when using CPT II codes.*





(KED) Kidney Health Evaluation for Patients With Diabetes

Measure evaluates the percentage of persons 18 to 85 years of age with diabetes (type 1 or 2) who received a kidney health evaluation, defined by **BOTH** an estimated glomerular filtration rate (eGFR) **AND** a urine albumin-creatinine ratio (uACR), on the same or different dates of service during the measurement period.

Persons are identified by at least two diabetes diagnoses during measurement period or PY or at least one diabetes diagnosis and at least one diabetes medication dispensing event.

Tips

- Conduct a diabetic visit with diabetic patients at least once per year.
- Educate persons on why good kidney function is important as they work to manage their health and diabetes.
- Help persons schedule their diabetes follow-up appointments and remind them of the care gaps that should be covered to include kidney function.
- Submit applicable codes.

Note the following gap closure criteria:

Persons who received **BOTH** an eGFR and a uACR during the measurement period on the same or different dates of service:

✓ **uACR** — a urine lab that may appear alone on lab report.

OR

✓ **Urine creatinine and quantitative urine albumin.** These two may appear on the lab report in addition to or without a uACR result.

To close the care gap with the urine creatinine and quantitative urine albumin, test **cannot** be completed more than four days apart.

Note: As a best practice, perform both urine tests on the same day.

Description	Codes*
eGFR**	CPT: 80047, 80048, 80050, 80053, 80069, 82565
AND	
Option 1: Quantitative Urine Albumin and Urine Creatinine**	CPT: 82043 and 82570
OR	
Option 2: Urine Albumin Creatinine Ration (uACR)**	LOINC: 13705-9, 14958-3, 14959-1, 30000-4, 32294-1, 44292-1, 59159-4, 76401-9, 77253-3, 77254-1, 89998-9, 9318-7

*Codes subject to change.

**Must perform both options 1 and 2 if eGFR is not done.





(PCE) Pharmacotherapy Management of COPD Exacerbation

Measure evaluates the percentage of COPD exacerbations for persons 40 years of age and older who had an acute inpatient discharge or ED visit on or between Jan. 1 to Nov. 30 of the measurement period and were dispensed appropriate medications.

Two rates are reported:

- 1 Dispensed a systemic **corticosteroid** (or there was evidence of an active prescription) **within 14 days of the event.**
- 2 Dispensed a **bronchodilator** (or there was evidence of an active prescription) **within 30 days of the event.**

A prescription is considered active if the “days’ supply” indicated on the date when the person was dispensed the prescription is the number of days or more between that date and the relevant date.

- ✓ For acute inpatient stay, the relevant date is the date of admission.
- ✓ For an ED visit, the relevant date is the date of service.

The measure is based on episodes of acute inpatient discharges and ED visits. It is possible for there to be multiple events for the same person.

Tips

- Support early recognition of COPD exacerbations, emphasizing the importance of seeking care timely to prevent complications and slow disease progression.
- Reinforce the importance of adhering to prescribed medications, especially systemic corticosteroids and bronchodilators. Encourage use of pillboxes, reminder applications, and/or enrolling in automatic refill programs to support adherence.
- Prioritize early detection and management of COPD exacerbations with corticosteroids and bronchodilators to reduce the risk of acute episodes and support long-term disease control.
- Facilitate timely follow-up appointments to ensure medication access. Confirm prescriptions are filled, and address barriers such as cost or transportation.
- Reconcile medications carefully with discharge summaries to avoid errors and ensure continuity of care.
- Ensure vaccinations are up to date, including influenza, pneumonia, COVID-19, Respiratory Syncytial Virus (RSV), and others, as appropriate.

Systemic Corticosteroid Medications			
Description	Prescription		
Glucocorticoids	<ul style="list-style-type: none"> • cortisone • methylprednisolone 	<ul style="list-style-type: none"> • dexamethasone • prednisolone 	<ul style="list-style-type: none"> • hydrocortisone • prednisone

(continued)



(PCE) Pharmacotherapy Management of COPD Exacerbation *(continued)*

Bronchodilator Medications			
Description	Prescription		
Anticholinergic Agents	<ul style="list-style-type: none"> acclidinium-bromide ipratropium 	<ul style="list-style-type: none"> umeclidinium tiotropium 	
Beta 2-Agonists	<ul style="list-style-type: none"> albuterol metaproterenol indacaterol 	<ul style="list-style-type: none"> levalbuterol formoterol oledaterol 	<ul style="list-style-type: none"> arformoterol salmeterol
Bronchodilator Combinations	<ul style="list-style-type: none"> albuterol-ipratropium budesonide-formoterol formoterol-mometasone glycopyrrolate-indacaterol Umeclidinium-vilanterol Olodaterol-tiotropium 	<ul style="list-style-type: none"> formoterol-acclidinium formoterol-glycopyrrolate fluticasone-salmeterol fluticasone-vilanterol fluticasone furoate-umeclidinium-vilanterol 	

(PCR) Plan All-Cause Readmissions

Measure evaluates for persons 18 years of age and older, the number of acute inpatient and observation stays during the measurement period that were followed by an unplanned acute readmission for any diagnosis within 30 days, and the predicted probability of an acute readmission.

Tips

- Maintain reserved appointment availability for patients to follow up within seven days after discharge to help avoid readmissions.
- Educate patients on the importance of following discharge instructions, receiving adequate follow-up care, medication adherence, and improving health literacy.
- Address Social Determinants of Health (SDoH) to ensure patients can afford their medications, have sustainable housing, their nutrition and transportation needs are met, etc.
- Submit applicable codes.

Description	Codes*
Inpatient Stay	UBREV: 0100, 0101, 0110–0114, 0116–0124, 0126–0134, 0136–0144, 0146–0154, 0156–0160, 0164, 0167, 0169–0174, 0179, 0190–0194, 0199–0204, 0206–0214, 0219, 1000–1002
Observation Stay	UBREV: 0760, 0762, 0769

*Codes subject to change.





(SPC-E) Statin Therapy for Patients With Cardiovascular Disease

The Statin Therapy for Patients With Cardiovascular Disease measure has transitioned to exclusive use of the Electronic Clinical Data Systems.

Measure evaluates the percentage of persons 21 to 75 years of age during the measurement period who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the criteria listed below.

The following rates are reported:

- 1 Received Statin Therapy.** Persons who were dispensed at least one high-intensity or moderate-intensity statin medication during the asurement period.
- 2 Statin Adherence 80%.** Persons who remained on a high-intensity or moderate intensity statin medication for at least 80% of the treatment period.

Note: Document patient muscular reactions to statins.



Tips

- Encourage patients to enroll in an auto-refill program at their pharmacy.
- Avoid giving samples. Any samples given will negatively impact adherence measurements and/or impact the “received statin therapy” rate.
- Offer tips to patients such as:
 - Take the medication at the same time each day.
 - Use a pill box.
 - Discuss potential side effects; encourage the person to contact the provider and not to stop using the medication.
- Review medication list during each visit with the patient.
- Discuss the importance of medication adherence with the patient.
- Retry with a different statin medication if person could not tolerate statin in the past.
- When appropriate, recommend providers prescribe extended days’ supply.

High-Intensity Statin Medications		
Description	Prescription	Medication Lists
High-intensity Statin Therapy	Atorvastatin 40–80 mg	Atorvastatin High Intensity Medications List
High-intensity Statin Therapy	Amlodipine-atorvastatin 40–80 mg	Amlodipine Atorvastatin High Intensity Medications List
High-intensity Statin Therapy	Rosuvastatin 20–40 mg	Rosuvastatin High Intensity Medications List
High-intensity Statin Therapy	Simvastatin 80 mg	Simvastatin High Intensity Medications List
High-intensity Statin Therapy	Ezetimibe-simvastatin 80 mg	Ezetimibe Simvastatin High Intensity Medications List

(continued)



(SPC-E) Statin Therapy for Patients With Cardiovascular Disease *(continued)*

Moderate-Intensity Statin Medications		
Description	Prescription	Medication Lists
Moderate-intensity Statin Therapy	Atorvastatin 10–20 mg	Atorvastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Amlodipine-atorvastatin 10–20 mg	Amlodipine Atorvastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Rosuvastatin 5–10 mg	Rosuvastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Simvastatin 20–40 mg	Simvastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Ezetimibe-simvastatin 20–40 mg	Ezetimibe Simvastatin Moderate Intensity Medication List
Moderate-intensity Statin Therapy	Pravastatin 40–80 mg	Pravastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Lovastatin 40 mg	Lovastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Fluvastatin 80 mg	Fluvastatin Moderate Intensity Medications List
Moderate-intensity Statin Therapy	Pitavastatin 2–4 mg	Pitavastatin Moderate Intensity Medications List



PHARMACY MEASURES



(SPD-E) Statin Therapy for Patients With Diabetes

The Statin Therapy for Patients with Diabetes measure has transitioned to exclusive use of the Electronic Clinical Data Systems.

Measure evaluates the percentage of persons 40 to 75 years of age during the measurement period with diabetes who did not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the criteria listed below.

Two rates are reported:

- 1 Received Statin Therapy.** Persons who were dispensed at least one statin medication of any intensity during the measurement period.
- 2 Statin Adherence 80%.** Persons who remained on a statin medication of any intensity for at least 80% of the treatment period.

Note: Document patient muscular reactions to statins.



WOMEN'S HEALTH



(BCS-E) Breast Cancer Screening

Measure evaluates the percentage of person 40 to 74 years of age who were recommended for routine breast cancer screening and had a mammogram to screen for breast cancer during the measurement period. One or more mammograms any time on or between Oct. 1 two years prior to the measurement period and the end of the measurement period.



Tips

- Schedule person's mammogram screening annually.
- Document the date and the specific procedure completed when reviewing the patient's history.
- Submit the appropriate ICD-10 diagnosis code for a person's history of bilateral mastectomy annually, Z90.13.
- Submit applicable codes.

Description	Codes*
Mammogram	CPT: 77061-77063, 77065-77067 ICD-10 (bilateral mastectomy): Z90.13
Palliative Care	HCPCS: G9054

*Codes subject to change.



(CCS-E) Cervical Cancer Screening

Measure evaluates the percentage of persons 21 to 64 years of age who were screened for cervical cancer during the measurement period using **any** of the following criteria:

- ✓ Persons 21 to 64 years of age who had cervical cytology performed within last three years.
- ✓ Persons 30 to 64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last five years.
- ✓ Persons 30 to 64 years of age who had cervical cytology/high risk human papillomavirus (hrHPV) co-testing within the last five years.



Tips

- Document and code if person has had a hysterectomy with no residual cervix or absence of cervix. Document the type of hysterectomy (e.g., full, partial, vaginal, laparoscopic).
- Help persons schedule their routine cervical cancer screening.

(continued)



(CCS-E) Cervical Cancer Screening *(continued)*

- Document the date and the specific procedure completed when reviewing the patient's history with result, or evidence of result.
- Submit the applicable codes.

Description	Codes*
Cervical Cytology Lab Test (Age 21 to 64)	CPT: 88141–88143, 88147, 88148, 88150, 88152, 88153, 88164–88167, 88174, 88175 HCPCS: G0123, G0124, G0141, G0143–G0145, G0147, G0148, P3000, P3001, Q0091
hrHPV Test (Age 30 to 64, every five years)	CPT: 87624–87626 HCPCS: G0476
Palliative Care	HCPCS: G9054

*Codes subject to change.



(CHL) Chlamydia Screening

Measure evaluates the percentage of persons 16 to 24 years of age who were recommended for routine chlamydia screening, were identified as sexually active, and had at least one test for chlamydia during the measurement period.



Tips

- Providers should order an annual chlamydia screening for patients who will turn 16 years old by Dec. 31 of the measurement period.
- Perform chlamydia screening every year.
- Inform patient that chlamydia screening can be performed through a urine test. Offer this as an option for patients.
- Incorporate chlamydia screening as a standard laboratory test for patients aged 16 to 24, to be included during routine well-child and well-woman examinations.
- Place chlamydia swab next to Pap test or pregnancy detection materials.
- Advise persons during wellness visits or when they are seen for birth control to get screened for chlamydia.
- Submit applicable codes.

CPT*

87110, 87270, 87320, 87490–87492, 87810

*Codes subject to change.





(DBM-E) Documented Assessment After Mammogram

Measure evaluates the percentage of episodes of mammograms during the measurement period documented in the form of a Breast Imaging Reporting and Data System (BI-RADS) assessment within 14 days of the mammogram for persons 40 to 74 years of age.

A higher rate indicates better performance.

Definitions:

✓ **BI-RADS assessment**

- Clinically documented BI-RADS score. BI-RADS is a standardized classification system proposed by the American College of Radiology, used for imaging of mammography, ultrasound, and magnetic resonance imaging (MRI) of the breast.

✓ **Episode date**

- The date of service for an eligible encounter during the intake period with a mammogram procedure.

✓ **Intake period**

- Dec. 18 of the prior measurement period to Dec. 17 of the measurement period. The intake period is used to capture the episode date.

BI-RADS Scoring Categories:

- ✓ **Category 0: Incomplete** — Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison, advises additional imaging.

- ✓ **Category 1: Negative** or **Category 2: Benign**, advises resuming routine screening.

- ✓ **Category 3: Probably Benign**, recommends diagnostic mammograms at 6 months, followed by repeat screenings every 6–12 months for 1–2 years, if appropriate.

- ✓ **Category 4: Suspicious** and **Category 5: Highly Suggestive of Malignancy**, the recommendation is for tissue diagnosis using core needle biopsy (preferred) or needle localization excisional biopsy with specimen radiograph. When a needle biopsy (aspiration or core needle biopsy) is performed, obtaining concordance between the pathology report and the imaging finding is crucial.

- ✓ For **Category 6: Known Biopsy-Proven Malignancy**, the recommendation depends on the primary tumor, size of the invasive component, estimated disease volume, histological grade, and other relevant characteristics.



Tips

- Document the BI-RADS score in the health record on or within 14 days after the mammogram (15 days total).
- Ensure all required elements of the mammogram report are documented, especially if not included in the original interpretation.
- After mammography, ensure clear communication of the BI-RADS assessment, including its implications for cancer risk and recommended screening follow-up.
- Educate persons with an inconclusive or high-risk BI-RADS assessment about the need for additional screening, such as ultrasound or MRI, as recommended by clinical guidelines.

(continued)



(DBM-E) Documented Assessment After Mammogram *(continued)*

- Engage radiologists, PCPs, and specialists to ensure appropriate care based on the mammogram results. Support smooth transitions between departments for timely diagnostic follow up.
- Submit applicable codes.

Description	Codes*
BI-RADS Assessment	RadLex: RID36028–RID36036, RID36041
	SNOMED: 397138000 Mammography assessment (Category 0) Need additional imaging evaluation
	SNOMED: 397140005 Mammography assessment (Category 1) Negative
	SNOMED: 397141009 Mammography assessment (Category 2) Benign finding
	SNOMED: 397143007 Mammography assessment (Category 3) Probably benign finding, short interval follow-up
	SNOMED: 397144001 Mammography assessment (Category 4) Suspicious abnormality, biopsy should be considered
	SNOMED: 397145000 Mammography assessment (Category 5) Highly suggestive of malignancy
	SNOMED: 6111000179101 Mammography assessment (Category 6) Known biopsy, proven malignancy
	SNOMED: 6121000179106 Mammography assessment (Category 4A) Suspicious abnormality, biopsy should be considered, low suspicion of malignancy
	SNOMED: 6131000179108 Mammography assessment (Category 4B) Suspicious abnormality, biopsy should be considered, moderate suspicion of malignancy
SNOMED: 6141000179100 Mammography assessment (Category 4C) Suspicious abnormality, biopsy should be considered, high suspicion of malignancy	

*Codes subject to change.





(FMA-E) Follow-Up After Abnormal Mammogram Assessment

Measure evaluates the percentage of episodes during the measurement period for persons 40 to 74 years of age with inconclusive or high-risk BI-RADS assessments who received appropriate follow-up within 90 days of the assessment.

A higher rate indicates better performance.

✓ **BI-RADS assessment**

- Clinically documented BI-RADS score. BI-RADS is a standardized classification system proposed by the American College of Radiology, used for the imaging of mammography, ultrasound, and MRI of the breast.

✓ **Episode date**

- The dates of service during the intake period when a high-risk or inconclusive BI-RADS score was documented.

✓ **Intake period**

- Oct. 3 of the year prior to the measurement period to Oct. 2 of the measurement period. The intake period is used to capture the episode date.



Tips

- Document the BI-RADS score and appropriate follow-up within 90 days of assessment in the health record.
- Document inconclusive or high-risk BI-RADS assessment if it is missing from the mammogram report.
- To meet follow-up guidelines, ensure that one of the following appropriate actions occurs:
 - A **breast biopsy** at or within 90 days (91 days total) for a Category 4 (Suspicious) or Category 5 (Highly Suggestive of Malignancy) BI-RADS score.
 - A **mammogram** or **ultrasound** at or within 90 days (91 days total) for a BI-RADS score of 0 (Incomplete – Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison).
- Foster coordination between radiology, primary care, and oncology to ensure BI-RADS assessment is included in the follow-up plans for persons with higher risk factors.
- Submit applicable codes.

(continued)



(FMA-E) Follow-Up After Abnormal Mammogram Assessment *(continued)*

Description	Codes*
Breast Biopsy	<p>CPT: 19081, 19083, 19085, 19100, 19101</p> <p>SNOMED: 10940003, 28768007, 42125001, 44578009, 116219004, 116220005, 116334007, 172086006, 237372000, 237375003, 237376002, 237377006, 237378001, 237379009, 265253005, 274331003, 287553003, 303689004, 307298009, 387736007, 432109009, 432157003, 432337008, 432550005, 433008009, 433685008, 433805008, 442963006, 445171002, 445437001, 448336005, 448689003, 709628007, 711508007, 723990008, 725936002, 736615002, 770568001, 770569009, 770570005, 771086002, 771625002, 785800009, 786883001, 866232001, 1179705005, 1179707002, 1179708007, 1220570007, 1220571006, 1220572004, 1264555004, 1264556003, 1268323005, 1268996004, 1332066007, 1332067003, 1333891002, 1333892009, 1333893004, 1333894005, 1333895006, 1333896007, 1333897003, 1333898008, 1333899000, 1333900005, 1333901009, 1333902002, 1333903007, 1333904001, 1333905000, 1333906004, 1334078005, 1334079002, 1334080004, 1356791009, 2131000087106, 2141000087100, 2841000087108, 4541000087104, 4551000087101, 5181000087103, 12131000087109, 305011000000108, 305051000000107, 305071000000103, 306371000000109, 306381000000106, 306641000000107, 306651000000105, 306671000000101, 307971000000105, 307981000000107, 308041000000102, 872731000000104</p>
Breast Ultrasound	<p>CPT: 76641, 76642</p> <p>LOINC: 105420-4, 105421-2, 24599-3, 24601-7, 26215-4, 26216-2, 26288-1, 26290-7, 42132-1</p>
High-Risk BI-RADS Assessment	<p>RadLex: RID36030-RID36034</p> <p>SNOMED: 397144001 Mammography assessment (Category 4) — Suspicious abnormality, biopsy should be considered</p> <p>SNOMED: 397145000 Mammography assessment (Category 5) — Highly suggestive of malignancy</p> <p>SNOMED: 6121000179106 Mammography assessment (Category 4A) — Suspicious abnormality, biopsy should be considered, low suspicion of malignancy</p> <p>SNOMED: 6131000179108 Mammography assessment (Category 4B) — Suspicious abnormality, biopsy should be considered, moderate suspicion of malignancy</p> <p>SNOMED: 6141000179100 Mammography assessment (Category 4C) — Suspicious abnormality, biopsy should be considered, high suspicion of malignancy</p>
Inconclusive BI-RADS	<p>RadLex: RID36036</p> <p>SNOMED: 397138000 Mammography assessment (Category 0) — Need additional imaging evaluation</p>
Mammography	<p>CPT: 77061-77063, 77065-77067</p> <p>LOINC: 103885-0, 103886-8, 103892-6, 103893-4, 103894-2, 24604-1, 24605-8, 24606-6, 24610-8, 26175-0, 26176-8, 26177-6, 26287-3, 26289-9, 26291-5, 26346-7, 26347-5, 26348-3, 26349-1, 26350-9, 26351-7, 36319-2, 36625-2, 36626-0, 36627-8, 36642-7, 36962-9, 37005-6, 37006-4, 37016-3, 37017-1, 37028-8, 37029-6, 37030-4, 37037-9, 37038-7, 37052-8, 37053-6, 37539-4, 37542-8, 37543-6, 37551-9, 37552-7, 37553-5, 37554-3, 37768-9, 37769-7, 37770-5, 37771-3, 37772-1, 37773-9, 37774-7, 37775-4, 38070-9, 38071-7, 38072-5, 38090-7, 38091-5, 38807-4, 38820-7, 38854-6, 38855-3, 42415-0, 42416-8, 46335-6, 46336-4, 46337-2, 46338-0, 46339-8, 46350-5, 46351-3, 46356-2, 46380-2, 48475-8, 48492-3, 69150-1, 69251-7, 69259-0, 72137-3, 72138-1, 72139-9, 72140-7, 72141-5, 72142-3, 86462-9, 86463-7, 91517-3, 91518-1, 91519-9, 91520-7, 91521-5, 91522-3</p>

*Codes subject to change.





(PPC) Prenatal and Postpartum Care

Measure evaluates percentage of live birth deliveries on or between Oct. 8 of the year prior to the measurement period and Oct. 7 of the measurement period. For these persons, the measure assesses the following facets of prenatal and postpartum care.

- ✓ **Timeliness of Prenatal Care:** Percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date, or within 42 days of enrollment in the organization.
- ✓ **Postpartum Care:** Percentage of deliveries that had a postpartum visit on or between seven and 84 days after delivery.



Tips

- Schedule an initial prenatal visit within the first 12 weeks of pregnancy with an obstetrician/gynecologist (OB/GYN), PCP, or nurse midwife.
- Educate persons on the importance of prenatal care throughout their pregnancy to include the postpartum visit.
- Ensure prenatal flow sheets and/or American College of Obstetricians and Gynecologists (ACOGs) person forms are fully completed, with dates of services and provider initials (if applicable).
- Schedule postpartum visits prior to discharge after delivery.
- Submit applicable codes.

Description	Codes*
Online Assessments	CPT: 98970–98972, 99421–99423, 99457 HCPCS: G0071, G2010, G2012
Prenatal Visits	CPT: 98980, 98981, 99202–99205, 99211–99215, 99242–99245, 99458, 99483 HCPCS: G0463, G2250–G2252, T1015
Stand-Alone Prenatal Visits	CPT: 99500 CPT II: 0500F, 0501F, 0502F HCPCS: H1000, H1001, H1002, H1003, H1004
Cervical Cytology Lab Test	CPT: 88141–88143, 88147, 88148, 88150, 88152–88153, 88164–88167, 88174, 88175 HCPCS: G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001
Postpartum Visits	CPT: 57170, 58300, 59430, 99501 CPT II: 0503F HCPCS: G0101 ICD-10: Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2
Telehealth Visits	CPT: 98000–98016, 98966–98968, 99441–99443

*Codes subject to change.

Note: When using the Online Assessment, Telephone Visit, or Prenatal Visit codes, remember to also include a Pregnancy Diagnosis code.





(PRS-E) Prenatal Immunization Status

Measure evaluates the percentage of deliveries in the measurement period in which persons had received influenza and Tdap vaccinations during the measurement period.

Measurement Period:

- ✓ **Flu** — on or between Jul. 1 of the year prior to the measurement period and the delivery date.
- ✓ **Tdap** — vaccine received during the pregnancy (including the delivery date).



Tips

- Identify persons with open care gaps and flag in EHR system if possible.
- Offer needed vaccines during prenatal visits and check-ups, or when person is admitted for delivery.
- Educate person on the importance of vaccinations and how they protect both person and baby, and address any fear or anxiety associated with vaccinations during pregnancy.
- Document all vaccinations in the person EMR.
- Submit applicable codes.

Description	Codes*
Adult Influenza Immunization	CVX: 88, 135, 140, 141, 144, 150, 153, 155, 158, 166, 168, 171, 185, 186, 197, 205, 320
Adult Influenza Vaccine Procedure	CPT: 90653, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756
Tdap Immunization	CVX: 115
Tdap Vaccine Procedure	CPT: 90715
Encephalitis	SNOMED: 192710009, 192711008, 192712001
Anaphylaxis	SNOMED: 428291000124105, 428281000124107

*Codes subject to change.



PEDIATRIC HEALTH



(CIS-E) Childhood Immunization Status

Measure evaluates the percentage of children two years of age during the measurement period who had four diphtheria, tetanus, and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (Hep B), one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and three combination rates.



Tips

- Document both the name of the vaccine and the date it was administered in the medical record.
- Submit applicable codes.

Description	Codes*
DTaP (4 doses)**	CPT: 90697, 90698, 90700, 90723 CVX: 20, 50, 106, 107, 110, 120, 146, 198
HiB (3 doses)**	CPT: 90644, 90647, 90648, 90697, 90698, 90748 CVX: 17, 46, 47, 48, 49, 50, 51, 120, 146, 148, 198
Hep B (3 doses) May include a newborn vaccination.	CPT: 90697, 90723, 90740, 90744, 90747, 90748 CVX: 08, 44, 45, 51, 110, 146, 198 HCPCS: G0010 ICD-10: B16.0, B16.1, B16.2, B16.9, B17.0, B18.0, B18.1, B19.10, B19.11
IPV (3 doses)**	CPT: 90697, 90698, 90713, 90723 CVX: 10, 89, 110, 120, 146
MMR (1 dose) If using history of illness to close MMR gap, there must be evidence of illness with all three measles, mumps, and rubella.	CPT: 90707, 90710 CVX: 03, 94 ICD-10: B05.0, B05.1, B05.2, B05.3, B05.4, B05.81, B05.89, B05.9, B26.0, B26.1, B26.2, B26.3, B26.81, B26.82, B26.83, B26.84, B26.85, B26.89, B26.9, B06.00, B06.01, B06.02, B06.09, B06.81, B06.82, B06.89, B06.9
Pneumococcal Conjugate PCV (4 doses)**	CPT: 90670, 90671, 90677 CVX: 109, 133, 152, 215, 216 HCPCS: G0009
Varicella VZV (1 dose)	CPT: 90710, 90716 CVX: 21, 94 ICD-10: B01.0, B01.11, B01.12, B01.2, B01.81, B01.89, B01.9, B02.0, B02.1, B02.21, B02.22, B02.23, B02.24, B02.29, B02.30, B02.31, B02.32, B02.33, B02.34, B02.39, B02.7, B02.8, B02.9

(continued)



(CIS-E) Childhood Immunization Status *(continued)*

Description	Codes*
Hep A (1 dose)	CPT: 90633 CVX: 31, 83, 85 ICD-10: B15.0, B15.9
Influenza (2 doses)*** LAIV meets criteria for one of the two required vaccinations if administered on the 2nd birthday.	CPT: 90655–90658, 90660, 90661, 90672–90674, 90685–90689, 90756 CVX: 88, 111, 140, 141, 149, 150, 153, 155, 158, 161, 171, 186, 320
Rotavirus (2 doses)**	CPT: 90681
Rotavirus (3 doses)**	CPT: 90680 CVX: 116, 122
Anaphylaxis	Please refer to the HEDIS Value Set Directory for applicable SNOMED codes for anaphylaxis and encephalitis.

*Codes subject to change.

**Do not count a vaccination administered prior to 42 days after birth.

***Do not count a vaccination administered prior to 180 days after birth.

Note: Rotavirus is either 2 dose **OR** 3 dose for compliancy.



(IMA-E) Immunizations for Adolescents

Measure evaluates the percentage of adolescents 13 years of age during the measurement period who had one dose of meningococcal vaccine, one Tdap vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates.



Tips

- Document both the name of the vaccine and the date it was administered in the medical record.
- Submit applicable codes.

Description	Codes*
Meningococcal (serogroups A, C, W, Y or A, C, W, Y, B) (1 dose) — must be administered between 10th and 13th birthday	CPT: 90619, 90623, 90624, 90733, 90734 CVX: 32, 108, 114, 136, 147, 167, 203, 316, 328
Tdap (1 dose) — must be administered between the 10th and 13th birthday	CPT: 90715
HPV (2 or 3 dose series) — must be administered between 9th and 13th birthday	CPT: 90649–90651 CVX: 62, 118, 137, 165
Anaphylaxis	Please refer to the HEDIS Value Set Directory for applicable SNOMED codes for anaphylaxis and encephalitis.

*Codes subject to change.





(LSC-E) Lead Screening in Children

The Lead Screening in Children measure has transitioned to exclusive use of the Electronic Clinical Data Systems.

Measure evaluates the percentage of children two years of age during the measurement period who had one or more capillary or venous lead blood tests for lead poisoning on or prior to their second birthday.

Only one test is required.



Tips

- Lead screening must be performed on or prior to child’s second birthday.
- Document both the date and results of the lead screening.
- Results of ‘unknown’ are not acceptable.
- Submit applicable codes.

CPT*

83655

*Codes subject to change.



(OED) Oral Evaluation, Dental Services

Measure evaluates the percentage of persons under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement period.



Tips

- Remind persons or their responsible party about dental benefits.
- Encourage regular check-up visits with a dentist for routine exams, cleanings, and oral x-rays.
- Help persons schedule an appointment to see a dentist.
- Federally Qualified Health Centers and Rural Health Clinics/ Centers can serve as a Primary Care Dental Home provider.

Description	Codes*
Dental Provider	Provider Taxonomy: 122300000X, 1223D0001X, 1223D0004X, 1223E0200X, 1223G0001X, 1223P0106X, 1223P0221X, 1223P0300X, 1223P0700X, 1223S0112X, 1223X0008X, 1223X0400X, 1223X2210X, 122400000X, 124Q00000X, 125J00000X, 125K00000X, 125Q00000X, 126800000X, 204E00000X, 261QD0000X, 261QF0400X, 261QR1300X, 261QS0112X
Oral Evaluation	CDT: D0120, D0145, D0150

*Codes subject to change.





(TFC) Topical Fluoride for Children

Measure evaluates the percentage of persons one to four years of age who received at least two fluoride varnish applications during the measurement period.



Tips

- Children must receive two fluoride varnish applications on different dates of services.
- During visits, educate parents about the importance of having children receive fluoride varnish applications.
- PCP can start applying fluoride varnish with the first tooth eruption and apply it every three to six months.
- Perform an Oral Health Risk Assessment to determine any risk factors.
- TFC treatment can be completed by a pediatrician or other qualified health care professional.

Description	Codes*
Topical Application of Fluoride Varnish	CPT: 99188 CDT: D1206
Application of Dental Fluoride Varnish (Procedure)	SNOMED CT US Edition: 313042009

*Codes subject to change.



(W30) Well-Child Visits in the First 30 Months of Life

Measure evaluates the percentage of children who had the following number of well-child visits with PCP during the measurement period.

The following rates are reported:

- 1 Well-Child Visits in the First 15 Months.** Children who turned 15 months old during the measurement period: Six or more well-child visits.
- 2 Well-Child Visits for Age 15 Months to 30 Months.** Children who turned 30 months old during the measurement period: Two or more well-child visits.



Tips

- Remind caregivers of appointments by texts or phone calls.
- Educate caregivers about the importance of preventive care visits.
- Consider using templates with checkboxes to ensure required information is documented.
- Submit applicable codes.

Note: Telehealth well visits are no longer acceptable.

CPT*	HCPCS*	ICD-10*
99381, 99382, 99391, 99392, 99461	S0302	Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z02.84, Z76.1, Z76.2

*Codes subject to change.





(WCC) Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

Measure evaluates the percentage of persons 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement period:

- ✓ Body Mass Index (BMI) percentile.
- ✓ Counseling for nutrition.
- ✓ Counseling for physical activity.



Tips

- Be sure to document all components of the WCC measure on every visit.
- Nutrition pertains to eating habits and behaviors (not appetite).
- BMI values are not acceptable, only percentiles. Ranges are not acceptable. If plotted on a chart, a BMI chart must be used (not age-growth chart).
- Call persons/caregivers to reschedule cancelled appointments.
- Include documentation if child/adolescent is counseled for weight or obesity.
- Submit applicable codes.

Description	Codes*
BMI Percentile	ICD-10: Z68.51, Z68.52, Z68.53, Z68.54, Z68.55, Z68.56 LOINC: 59574-4, 59575-1, 59576-9
Nutrition Counseling	CPT: 97802–97804 HCPCS: G0270, G0271, G0447, S9449, S9452, S9470 ICD-10: Z71.3
Physical Activity	HCPCS: G0447, S9451 ICD-10: Z02.5, Z71.82

*Codes subject to change.





(WCV) Child and Adolescent Well-Care Visits

Measure evaluates the percentage of persons 3 to 21 years of age who had at least one comprehensive well-care visit with a PCP or OB/GYN within the measurement period.



Tips

- Remind caregivers of appointments by texts or phone calls.
- Educate caregivers about the importance of preventive care visits to assess growth and development and to provide immunizations and anticipatory guidance on nutrition, physical activity, and safety.
- Components of a WCV should include a health history, physical development history, and mental development history along with:
 - A physical exam (including height, weight, and BMI percentile).
 - Health education and anticipatory guidance.

Note: Telehealth well visits are no longer acceptable.

CPT*	HCPCS*	ICD-10*
99382–99385, 99391–99395	G0438, G0439, S0302, S0610, S0612, S0613	Z00.00, Z00.01, Z00.121, Z00.129, Z00.2, Z00.3, Z01.411, Z01.419, Z02.5, Z76.1, Z76.2

*Codes subject to change.



GENERAL HEALTH



(AAB) Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis

Measure evaluates the percentage of episodes for persons three months of age and older with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event on or three days after the episode.

Looks at eligible outpatient, telephone, ED visits, e-visits, or virtual check-ins with a diagnosis of acute bronchitis/bronchiolitis during the intake period from Jul. 1 of the year prior to the measurement period to Jun. 30 of the measurement period that did not result in an inpatient stay.

A higher rate indicates appropriate acute bronchitis/bronchiolitis treatment (i.e., the proportion of episodes that did not result in an antibiotic dispensing event).

Tips

- When clinically appropriate, suggest alternate symptom management options, such as over-the-counter medications, humidifiers, adequate fluids and rest, and other non-pharmacologic therapies.
- Avoid prescribing antibiotics for acute bronchitis or bronchiolitis in uncomplicated cases, as these conditions are typically viral and self-limiting.
- If clinical indications warrant antibiotic therapy, document the appropriate diagnosis to support the prescribed treatment.
- Ensure persons receive recommended respiratory vaccinations (e.g., influenza, pneumococcal, COVID-19, RSV) based on clinical guidelines and personal risk factors to help reduce the risk of infections that may mimic or contribute to acute bronchitis.
- Submit applicable codes.

Description	Codes*
Acute Bronchitis	ICD-10: J20.3-J20.9, J21.0, J21.1, J21.8, J21.9

*Codes subject to change.





(AAF-E) Follow-Up After Acute and Urgent Care Visits for Asthma

The percentage of persons 5 to 64 years of age with an urgent care visit, acute inpatient discharge, observation stay discharge, or ED visit with a diagnosis of asthma that had a corresponding outpatient follow-up visit with a diagnosis of asthma within 30 days.

✓ **An asthma episode is defined as an encounter between Jan. 1 and Dec. 1 with a diagnosis of asthma.**

- For urgent care visits that result in an ED visit, the ED visit is the episode.
- For urgent care or ED visits that result in a nonacute inpatient stay, the urgent care or ED visit is the episode.
- For acute inpatient or observation stays that result in a nonacute inpatient stay, the acute inpatient or observation stay discharge is the episode.

✓ **The asthma episode date is the date of service for the asthma episode.**

- For acute inpatient or observation stay discharges, the episode date is the date of discharge.
- For direct transfers, the episode date is the discharge date from the last transfer admission.
- For ED or urgent care visits, the episode date is the date of service.

Note: Do not include persons with a diagnosis of cystic fibrosis in the measure. Do not include laboratory claims with POS 81.

Description	Codes*
Outpatient and Telehealth	CPT: 98000–98016, 98966–98968, 98970–98972, 98980, 98981, 99202–99205, 99211, 99215, 99242–99245, 99341, 99342, 99344, 99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99421–99423, 99429, 99441–99443, 99455–99458, 99483
Asthma	ICD-10: J45.20, J45.21, J45.22, J45.30, J45.31, J45.32, J45.40, J45.41, J45.42, J45.50, J45.51, J45.52, J45.901, J45.902, J45.909, J45.990, J45.991, J45.998

*Codes subject to change.





(CWP) Appropriate Testing for Pharyngitis

Measure evaluates the percentage of episodes for persons three years of age and older where the person was **diagnosed with pharyngitis, dispensed an antibiotic, and received a group A streptococcus (strep) test** in the seven-day period: from three days *prior* to the episode date through three days after the episode.

Measure looks at eligible outpatient, telephone, ED visits, e-visits, or virtual check-ins with a diagnosis of acute pharyngitis during the intake period from Jul. 1 of the year prior to the measurement period to Jun. 30 of the measurement period that did not result in an inpatient stay.



Tips

- Perform a group A strep test (rapid antigen or throat culture) in persons who present with symptoms suggestive of strep throat before prescribing antibiotics.
- For persons with viral pharyngitis, offer guidance on supportive care, including over-the-counter analgesics, throat lozenges, oral rinses, hydration, and rest as clinically appropriate to effectively manage symptoms.
- Review and clearly document the group A strep test in the health record. Prescribe antibiotics for pharyngitis only when the test is positive.
- Submit applicable codes.

Description	Codes*
Group A Strep Test	CPT: 87070, 87071, 87081, 87430, 87650-87652, 87880
Pharyngitis	ICD-10: J02.0, J02.8, J02.9, J03.00, J03.01, J03.80, J03.81, J03.90, J03.91

*Codes subject to change.

Antibiotic Medications	
Description	Prescriptions
Aminopenicillins	• amoxicillin • ampicillin
Beta-Lactamase Inhibitors	• amoxicillin-clavulanate
First-Generation Cephalosporins	• cefadroxil • cefazolin • cephalexin
Folate Antagonist	• trimethoprim
Lincomycin Derivatives	• clindamycin
Macrolides	• azithromycin • clarithromycin • erythromycin
Natural Penicillins	• penicillin G benzathine • penicillin G potassium • penicillin G sodium • penicillin V potassium
Quinolones	• ciprofloxacin • levofloxacin • moxifloxacin • ofloxacin
Second-Generation Cephalosporins	• cefaclor • cefprozil • cefuroxime
Sulfonamides	• sulfamethoxazole-trimethoprim
Tetracyclines	• doxycycline • minocycline • tetracycline
Third-Generation Cephalosporins	• cefdinir • cefixime • cefpodoxime • ceftriaxone





(LBP) Use of Imaging Studies for Low Back Pain

Measure evaluates the percentage of persons 18 to 75 years of age with a principal diagnosis of low back pain who did not have an imaging study (i.e., plain X-ray, MRI, CT scan) within 28 days of the diagnosis.

The Index Episode Start Date (IESD) is the earliest eligible date of service during the Intake Period (Jan. 1 through Dec. 3 of the measurement period) when a person presents with a principal diagnosis of low back pain and has no claims or encounters for low back pain in the 180 days prior to that date.

A higher score indicates appropriate treatment of low back pain (i.e., the proportion for whom imaging studies **did not** occur).

Excludes persons who meet any of the following criteria:

- ✓ Inpatient stays or visits resulting in an inpatient stay.
- ✓ Deceased, or receiving hospice or palliative care during the measurement period.
- ✓ Age 66+ with both frailty and advanced illness (including use of dementia medications).
- ✓ Medical history that may justify imaging within specified timeframes, such as:
 - Cancer, HIV, history of organ transplant, osteoporosis, or spondylopathy.
 - Lumbar surgery or medication treatment for osteoporosis.
 - IV drug use, neurologic impairment, or spinal infection.
 - Trauma or fragility fractures.
 - Prolonged corticosteroid use (≥90 consecutive days).



Tips

- If not medically required, avoid ordering diagnostic studies (i.e., plain X-ray, MRI, CT scan) for the diagnosis of uncomplicated low back pain in the absence of red flags (e.g., cancer, recent trauma, neurologic impairment, or IV drug abuse).
- When clinically indicated, provide person with education on cautious pain relief measures such as over-the-counter analgesics, activity modifications, and the use of ice and/or heat.
- If medically appropriate, consider physical therapy or other interventions such as massage, stretching, strengthening exercises, and manipulation.
- Assess for other contributing factors to low back pain (e.g., depression, anxiety, narcotic dependence, psychosocial stressors) and address them as clinically appropriate.
- Ensure timely and accurate submission of claims and encounter data to reflect care provided.
- Submit applicable codes.

(continued)



(LBP) Use of Imaging Studies for Low Back Pain *(continued)*

Description	Codes*
Imaging Study	CPT: 72020, 72040, 72050, 72052, 72070, 72072, 72074, 72080–72084, 72100, 72110, 72114, 72120, 72125–72133, 72141, 72142, 72146–72149, 72156–72158, 72200, 72202, 72220
Uncomplicated Low Back Pain	ICD-10: M47.26–M47.28, M47.816–M47.818, M47.896–M47.898, M48.061, M48.07, M48.08, M51.16, M51.17, M51.26, M51.27, M51.36, M51.360, M51.362, M51.369, M51.37, M51.370, M51.372, M51.379, M51.86, M51.87, M53.2X6–M53.2X8, M53.3, M53.86–M53.88, M54.16–M54.18, M54.30–M54.32, M54.40–M54.42, M54.5, M54.50, M54.51, M54.59, M54.89, M54.9, M99.03, M99.04, M99.23, M99.33, M99.43, M99.53, M99.63, M99.73, M99.83, M99.84, S33.100A, S33.100D, S33.100S, S33.110A, S33.110D, S33.110S, S33.120A, S33.120D, S33.120S, S33.130A, S33.130D, S33.130S, S33.140A, S33.140D, S33.140S, S33.5XXA, S33.6XXA, S33.8XXA, S33.9XXA, S39.002A, S39.002D, S39.002S, S39.012A, S39.012D, S39.012S, S39.092A, S39.092D, S39.092S, S39.82XA, S39.82XD, S39.82XS, S39.92XA, S39.92XD, S39.92XS

*Codes subject to change.



(SNS-E) Social Needs Screening and Intervention

Measure evaluates the percentage of persons (all ages) who were screened using prespecified instruments at least once during the measurement period for unmet food, housing, and transportation needs, and received a corresponding intervention if they screened positive during the measurement period.

Six rates are reported:

- ✓ **Food Screening.** The percentage of persons who were screened for food insecurity.
- ✓ **Food Intervention.** The percentage of persons who received a corresponding intervention within 30 days (one month) of screening positive for food insecurity.
- ✓ **Housing Screening.** The percentage of persons who were screened for housing instability, homelessness, or housing inadequacy.
- ✓ **Housing Intervention.** The percentage of persons who received a corresponding intervention within 30 days (one month) of screening positive for housing instability, homelessness, or housing inadequacy.
- ✓ **Transportation Screening.** The percentage of persons who were screened for transportation insecurity.
- ✓ **Transportation Intervention.** The percentage of persons who received a corresponding intervention within 30 days (one month) of screening positive for transportation insecurity.

The SNS-E screening numerator counts only screenings that use instruments in the measure specification as identified by the associated LOINC® code(s).

The SNS-E measure specification does not prohibit cultural adaptations or linguistic translations from being counted toward the measure's screening numerators.

Only screenings documented using the LOINC codes specified in the SNS-E measure count toward the measure's screening numerators. Some screening tools are proprietary and may require licensing agreements or costs.

(continued)



(SNS-E) Social Needs Screening and Intervention *(continued)*

Food Insecurity Instruments	Screening Item LOINC Codes	Positive Finding LOINC Codes
Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool	88122-7 88123-5	LA28397-0 LA6729-3
American Academy of Family Physicians (AAFP) Social Needs Screening Tool	88122-7 88123-5	LA28397-0 LA6729-3
American Academy of Family Physicians (AAFP) Social Needs Screening Tool — Short Form	88122-7 88123-5	LA28397-0 LA6729-3
Health Leads Screening Panel ^{®1}	95251-5	LA33-6
Hunger Vital Sign ^{™1} (HVS)	88124-3	LA19952-3
Protocol for Responding to and Assessing Persons' Assets, Risks and Experiences (PRAPARE) ^{®1}	93031-3	LA30125-1
Safe Environment for Every Kid (SEEK) ^{®1}	95400-8 95399-2	LA33-6
U.S. Household Food Security Survey (U.S. FSS)	95264-8	LA30985-8 LA30986-6
U.S. Adult Food Security Survey (U.S. FSS)	95264-8	LA30985-8 LA30986-6
U.S. Child Food Security Survey (U.S. FSS)	95264-8	LA30985-8 LA30986-6
U.S. Household Food Security Survey — Six-Item Short Form (U.S. FSS)	95264-8	LA30985-8 LA30986-6
We Care Survey	96434-6	LA32-8
WellRx Questionnaire	93668-2	LA33-6
Housing Instability and Homelessness Instruments	Screening Item LOINC Codes	Positive Finding LOINC Codes
Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool	71802-3	LA31994-9 LA31995-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool	99550-6	LA33-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool — Short Form	71802-3	LA31994-9 LA31995-6
Children's Health Watch Housing Stability Vital Signs [™]	98976-4 98977-2 98978-0	LA33-6 ≥2
Health Leads Screening Panel ^{®1}	99550-6	LA33-6
Protocol for Responding to and Assessing Persons' Assets, Risks and Experiences (PRAPARE) ^{®1}	93033-9 71802-3	LA33-6 LA30190-5
We Care Survey	96441-1	LA33-6
WellRx Questionnaire	93669-0	LA33-6

¹Proprietary; cost or licensing requirement may be associated with use.

(continued)



(SNS-E) Social Needs Screening and Intervention *(continued)*

Housing Inadequacy Instruments	Screening Item LOINC Codes	Positive Finding LOINC Codes
Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool	96778-6	LA31996-4 LA28580-1 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2
American Academy of Family Physicians (AAFP) Social Needs Screening Tool	96778-6	LA32691-0 LA28580-1 LA32693-6 LA32694-4 LA32695-1 LA32696-9 LA32001-2
American Academy of Family Physicians (AAFP) Social Needs Screening Tool — Short Form	96778-6	LA31996-4 LA28580-1 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2
Norwalk Community Health Center Screening Tool (NCHC)	99134-9 99135-6	LA31996-4 LA28580-1 LA31997-2 LA31998-0 LA31999-8 LA32000-4 LA32001-2
Transportation Insecurity Instruments	Screening Item LOINC Codes	Positive Finding LOINC Codes
Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool	93030-5	LA33-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool	99594-4	LA33-6
American Academy of Family Physicians (AAFP) Social Needs Screening Tool — Short Form	99594-4	LA33093-8 LA30134-3
Comprehensive Universal Behavior Screen (CUBS)	89569-8	LA29232-8 LA29233-6 LA29234-4
Health Leads Screening Panel ^{®1}	99553-0	LA33-6

¹Proprietary; cost or licensing requirement may be associated with use.

(continued)



(SNS-E) Social Needs Screening and Intervention *(continued)*

Transportation Insecurity Instruments	Screening Item LOINC Codes	Positive Finding LOINC Codes
Inpatient Rehabilitation Facility — Patient Assessment Instrument (IRF-PAI) — version 4.0 (CMS Assessment)	101351-5	LA30133-5 LA30134-3
Outcome and Assessment Information Set (OASIS) Form — version E — Discharge from Agency (CMS Assessment)	101351-5	LA30133-5 LA30134-3
Outcome and Assessment Information Set (OASIS) Form — version E — Resumption of Care (CMS Assessment)	101351-5	LA30133-5 LA30134-3
Outcome and Assessment Information Set (OASIS) Form — version E — Start of Care (CMS Assessment)	101351-5	LA30133-5 LA30134-3
Protocol for Responding to and Assessing Patients’ Assets, Risks and Experiences (PRAPARE) ¹	93030-5	LA30133-5 LA30134-3
PROMIS ^{®1}	92358-1	LA30024-6 LA30026-1 LA30027-9
WellRx Questionnaire	93671-6	LA33-6

- ✓ Identify persons with positive screening and conduct an intervention corresponding to the type of need identified on or up to 30 days after the date of the first positive screening during the measurement period.



Tips

- Interventions may include any of the following categories: adjustment, assistance, coordination, counseling, education, evaluation of eligibility, evaluation/assessment, provision, or referral.

Description	Codes*
Food Insecurity Procedures	CPT: 97802–97804 HCPCS: S5170 (Home delivered meals, including preparation; per meal) HCPCS: S9470 (Nutritional counseling, dietitian visit)
Food Insecurity (must be associated with Food Interventions)	ICD-10: Z59.41 and Z59.48
Administration of a Standardized, Evidence-Based Social Determinants of Health Risk Assessment Tool, 5–15 Minutes	HCPCS: G0136
Homelessness Diagnosis	ICD-10: Z59.00–Z59.02
Housing Inadequacy	ICD-10: Z59.10–Z59.12; Z59.19

*Codes subject to change.

¹Proprietary; cost or licensing requirement may be associated with use.





(TSC-E) Tobacco Use Screening and Cessation Intervention

Measure evaluates the percentage of persons 12 years of age and older who were screened for commercial tobacco product use at least once during the measurement period, and who received tobacco cessation intervention if identified as a tobacco user.

Two rates are reported:

- 1 Tobacco Use Screening.** The percentage of persons who were screened for tobacco use.
 - 2 Cessation Intervention.** The percentage of persons who were identified as a tobacco user and who received tobacco cessation intervention.
- ✓ A positive tobacco user is a person who was screened for tobacco use and had a documented positive result. Any of the following meet criteria:
 - Tobacco Use Screening Value Set with Yes Value Set.
 - LOINC code 72166-2 with Positive Tobacco Use Status Value Set.
 - ✓ A negative tobacco user is a person who was screened for tobacco use and had a documented negative result. Any of the following meet criteria:
 - Tobacco Use Screening Value Set with No Value Set.
 - LOINC code 72166-2 with Negative Tobacco Use Status Value Set.

Description	Codes*
Positive Tobacco Use Status Note: Do not include laboratory claims (claims with POS code 81).	LOINC: LA18976-3, LA18977-1, LA18981-3, LA18982-1
Tobacco Use Cessation Counseling	CPT: 99406, 99407

*Codes subject to change.





(URI) Appropriate Treatment for Upper Respiratory Infection

Measure evaluates the percentage of episodes for persons three months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event on or three days after the episode.

Measure looks at eligible outpatient, telephone, ED visits, e-visits, or virtual check-ins with a diagnosis of URI during the intake period from Jul. 1 of the year prior to the measurement period to Jun. 30 of the measurement period that did not result in an inpatient stay.

A higher rate indicates appropriate URI treatment (i.e., the proportion of episodes that **did not** result in an antibiotic dispensing event).



Tips

- Unless clinically indicated, discourage antibiotics for routine treatment of uncomplicated viral infections, such as common colds, which are usually self-limiting and do not require antibiotic therapy.
- Provide clear instructions on supportive care and symptom management.
- When antibiotics are not indicated, recommend symptom management strategies such as fluids, rest, over-the-counter medications, and nasal saline to support recovery and minimize unnecessary antibiotic prescribing.
- Submit applicable codes.

Description	Codes*
Acute Nasopharyngitis (common cold)	ICD-10: J00
Acute Laryngopharyngitis	ICD-10: J06.0
Acute Upper Respiratory Infection, Unspecified	ICD-10: J06.9

*Codes subject to change.



SOCIAL DETERMINANTS OF HEALTH



(SDOH) Social Determinants of Health

Description	Codes*
Occupational Exposure to Risk Factors	ICD-10: Z57.0–Z57.9
Problems Related to Education and Literacy	ICD-10: Z55.0–Z55.9
Problems Related to Employment and Unemployment	ICD-10: Z56.0–Z56.9
Problems Related to Physical Environment	ICD-10: Z58.0–Z58.9
Problems Related to Housing and Economic Circumstances	ICD-10: Z59.0–Z59.9
Problems Related to Social Environment	ICD-10: Z60.0–Z60.9
Problems Related to Upbringing	ICD-10: Z62.0–Z62.9
Problems Related to Primary Support Group, Including Family Circumstances	ICD-10: Z63.0–Z63.9
Problems Related to Certain Psychosocial Circumstances	ICD-10: Z64.0–Z64.4
Problems Related to Other Psychosocial Circumstances	ICD-10: Z65.0–Z65.9
CPT/HCPCS Screening Codes Applicable to SDOH	CPT: 96156–96161, 97802–97804, 99377–99378 HCPCS: S5170, S9470, G0182, G9473–G9479, Q5003–Q5008, Q5010, S9126, T2042–T2046
Other Risk Factors	ICD-10: Z91.89

*Codes subject to change.



Best Practices:

Include supplemental codes in the diagnosis section of a person's claim form. Assign as many SDOH codes necessary to describe all the social problems, conditions, or risk factors documented during the current episode of care.





(ADD-E) Follow-up Care for Children Prescribed ADHD Medication

Time frame is measurement period.

Measure evaluates the percentage of children newly prescribed attention deficit hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 300-day (10-month) period, one of which was within 30 days of when the first ADHD medication was dispensed.

Two rates are reported:

- 1 Initiation Phase:** percentage of persons 6 to 12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase.
- 2 Continuation and Maintenance (C&M) Phase:** percentage of persons 6 to 12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (nine months) after the Initiation Phase ended.



Tips

- Complete a comprehensive medical and psychiatric exam, including rating scales from parents and teachers, before diagnosing and prescribing.
- Limit the first prescription of ADHD medication to a 28- to 30-day supply and schedule follow-up before the family leaves the office.
- Re-evaluate medication effectiveness no more than 30 days after initiation via telehealth when available, and regularly monitor medication effects thereafter.
- Periodically review the ongoing need for continued medication therapy.
- Reschedule any canceled appointments right away.
- Schedule telehealth visits if office visits are not acceptable.
- Submit applicable codes.

(continued)



(ADD-E) Follow-up Care for Children Prescribed ADHD Medication *(continued)*

Description	Codes*
Visit Setting Unspecified	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255 POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52, 53, 71, 72
BH Outpatient Visit	CPT: 98000–98006, 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245, 99341–99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99492–99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, G0560, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020, T1015
Health and Behavior Assessment/Intervention	CPT: 96156, 96158, 96159, 96164, 96165, 96167, 96168, 96170, 96171
Partial Hospitalization/ Intensive Outpatient	HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485
Telehealth Visit	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255 POS: 02, 10
Telephone Visits	CPT: 98966–98968, 99441–99443
E-visit/Virtual Check-in	CPT: 98970–98972, 98980, 98981, 99421–99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250–G2252
Visit Setting Unspecified Value Set with Community Mental Health Center POS	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255 POS: 53

*Codes subject to change.





(APM-E) Metabolic Monitoring for Children and Adolescents on Antipsychotics

Applicable Foster Care Measure

Measure evaluates the percentage of children and adolescents 1 to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing during the measurement period.

Three rates reported:

- 1 Percentage of children and adolescents on antipsychotics who **received blood glucose testing**.
- 2 Percentage of children and adolescents on antipsychotics who **received cholesterol testing**.
- 3 Percentage of children and adolescents on antipsychotics who **received blood glucose and cholesterol testing**.



Tips

- Provide persons/caregivers with lab orders for HbA1c or glucose and cholesterol or LDL-C to be completed yearly.
- Coordinate care between behavioral and physical health providers.
- Educate the person and caregiver about the risks associated with taking antipsychotic medications and the importance of regular follow-up care.
- Submit applicable codes.

Description (Need either A1c or Glucose and LCL-C or Cholesterol)	Codes*
HbA1c Lab Tests	CPT: 83036, 83037 CPT II: 3044F, 3046F, 3051F, 3052F
Glucose Lab Tests	CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
LDL-C Lab Tests	CPT: 80061, 83700, 83701, 83704, 83721 CPT II: 3048F, 3049F, 3050F
Cholesterol Lab Tests	CPT: 82465, 83718, 83722, 84478

*Codes subject to change.

Note: Do **not** include a modifier when using CPT II codes.





(APP) Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics

Measure evaluates the percentage of children and adolescents 1 to 17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.

Identify persons eligible for antipsychotic medications and provide psychosocial care from 90 days prior to 30 days after beginning a medication.



Tips

- Before prescribing antipsychotic medication, complete or refer for a trial of first-line psychosocial care.
- Antipsychotic medications should be part of a comprehensive, multi-modal plan for coordinated treatment that includes psychosocial care.
- The need for continued therapy with antipsychotic medications should be reviewed periodically.

Description	Codes*
Psychosocial Care or Residential Behavioral Health Treatment	CPT: 90832–90834, 90836–90840, 90845–90849, 90853, 90875, 90876, 90880 HCPCS: G0176, G0177, G0409–G0411, H0004, H0035–H0039, H0040, H2000, H2001, H2011–H2014, H2017–H2020, S0201, S9480, S9484, S9485
Residential Behavioral Health Treatment	HCPCS: H0017–H0019, T2048

*Codes subject to change.



(ASF-E) Unhealthy Alcohol Use Screening and Follow-Up

Measure evaluates the percentage of persons 18 years of age and older who were screened for unhealthy alcohol use using a standardized instrument between Jan. 1 and Nov. 1 of the measurement period and, if screened positive, received appropriate follow-up care.

Two rates are reported:

- 1 Unhealthy Alcohol Use Screening.** The percentage of persons who had a systematic screening for unhealthy alcohol use.
- 2 Follow-Up Care on Positive Screen.** The percentage of persons receiving brief counseling or other follow-up care within 60 days (2 months) of screening positive for unhealthy alcohol use.

Note: A LOINC code submission via flat file is required to be adherent for the screening numerator.



Tips

- Train staff on the importance of screenings and recognizing the risk factors for unhealthy alcohol use.
- Develop a workflow that includes utilizing a standardized instrument for unhealthy alcohol screenings at least annually.

(continued)



(ASF-E) Unhealthy Alcohol Use Screening and Follow-Up *(continued)*

- Ask your provider relations representative about ways to submit data to the health plan directly from your EHR/EMR.
- Document follow up on positive screen on or up to 60 days after the first positive screen.

Unhealthy Alcohol Screening instrument: A standard assessment instrument that has been normalized and validated for the adult patient population. Eligible screening instruments with thresholds for positive findings for numerator 1 include:

Screening Instruments	Total Score LOINC Codes	Positive Finding
Alcohol Use Disorders Identification Test (AUDIT) Screening Instrument	75624-7	Total score ≥ 8
Alcohol Use Disorders Identification Test Consumption (AUDIT-C) Screening Instrument	75626-2	Total score ≥ 4 for men Total score ≥ 3 for women
Single-Question Screen (for men): “How many times in the past year have you had 5 or more drinks in a day?”	88037-7	Response ≥ 1
Single-Question Screen (for women and all adults older than 65 years): “How many times in the past year have you had 4 or more drinks in a day?”	75889-6	Response ≥ 1

- ✓ If the unhealthy alcohol screening is positive, the person must receive alcohol counseling or other follow-up care within 60 days of the first positive screen.

Description	Codes*
Alcohol Counseling or Other Follow Up Care	CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, G2011, H0005, H0007, H0015, H0016, H0022, H00050, H2035, H2036, T1006, T1012
A Diagnosis of Encounter for Alcohol Counseling and Surveillance	ICD-10: Z71.41

*Codes subject to change.





(COU) Risk of Continued Opioid Use

Measure evaluates the percentage of persons 18 years of age and older who have a new episode of opioid use that puts them at risk for continued opioid use.

Two rates are reported:

- 1 The percentage of persons with **at least 15 days of prescription opioids in a 30-day period.**
- 2 The percentage of persons with **at least 31 days of prescription opioids in a 62-day period.**

Decreased numerator score indicates improvement.



Tips

- Educate on opioid safety and risk associated with long-term use and use of multiple opioids from different providers.
- Involve person in decisions to initiate or continue opioid use, only prescribe opioids when medically necessary, in the lowest effective dose, for the shortest duration necessary.

Use all the medication lists below to identify opioid medication dispensing events

- | | |
|--|--|
| • Acetaminophen Benzhydrocodone Medications List | • Meperidine Medications List |
| • Buprenorphine Medications List | • Methadone Medications List |
| • Butorphanol Medications List | • Morphine Medications List |
| • Acetaminophen Butalbital Caffeine Codeine Medications List | • Belladonna Opium Medications List |
| • Acetaminophen Codeine Medications List | • Opium Medications List |
| • Aspirin Butalbital Caffeine Codeine Medications List | • Acetaminophen Oxycodone Medications List |
| • Aspirin Carisoprodol Codeine Medications List | • Aspirin Oxycodone Medications List |
| • Codeine Sulfate Medications List | • Ibuprofen Oxycodone Medications List |
| • Acetaminophen Caffeine Dihydrocodeine Medications List | • Oxycodone Medications List |
| • Fentanyl Medications List | • Oxymorphone Medications List |
| • Acetaminophen Hydrocodone Medications List | • Naloxone Pentazocine Medications List |
| • Hydrocodone Medications List | • Tapentadol Medications List |
| • Hydrocodone Ibuprofen Medications List | • Acetaminophen Tramadol Medications List |
| • Hydromorphone Medications List | • Tramadol Medications List |
| • Levorphanol Medications List | |





(DSF-E) Depression Screening and Follow-Up for Adolescents and Adults

Measure evaluates the percentage of persons 12 years of age and older who were screened for clinical depression during the measurement period using a standardized instrument and, if screened positive, received follow-up care.

Two rates are reported:

- 1 Depression Screening.** The percentage of persons who were screened for clinical depression using a standardized instrument.
- 2 Follow-Up on Positive Screen.** The percentage of persons who received follow-up care within 30 days of a positive depression screen finding.

Depression screening instrument: A standard assessment instrument that has been normalized and validated for the appropriate person population.

The following table includes eligible screening instruments with thresholds for positive findings.

Instruments for Adolescents (≤17 years)	Total Score LOINC Codes	Positive Finding
Patient Health Questionnaire (PHQ-9) [®]	44261-6	Total score ≥10
Patient Health Questionnaire Modified for Teens (PHQ-9M) [®]	89204-2	Total score ≥10
Patient Health Questionnaire-2 (PHQ-2) [®]	55758-7	Total score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS) [®]	89208-3	Total score ≥8
Center for Epidemiologic Studies Depression Scale — Revised (CESD-R)	89205-9	Total score ≥17
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥10
PROMIS Depression	71965-8	Total score ≥60
Instruments for Adults (18+ years)	Total Score LOINC Codes	Positive Finding
Patient Health Questionnaire (PHQ-9) [®]	44261-6	Total score ≥10
Patient Health Questionnaire-2 (PHQ-2) [®]	55758-7	Total score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS) [®]	89208-3	Total score ≥8
Beck Depression Inventory (BDI-II)	89209-1	Total score ≥20
Center for Epidemiologic Studies Depression Scale — Revised (CESD-R)	89205-9	Total score ≥17
Duke Anxiety — Depression Scale (DUKE-AD) [®]	90853-3	Total score ≥30
Geriatric Depression Scale Short Form (GDS)	48545-8	Total score ≥5
Geriatric Depression Scale Long Form (GDS)	48544-1	Total score ≥10
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥10
My Mood Monitor (M-3) [®]	71777-7	Total score ≥5
PROMIS Depression	71965-8	Total score ≥60
PROMIS Emotional Distress — Depression — Short Form	77861-3	Total score ≥60
Clinically Useful Depression Outcome Scale (CUDOS)	90221-3	Total score ≥31

(continued)



(DSF-E) Depression Screening and Follow-Up for Adolescents and Adults *(continued)*



Tips

- Use age-appropriate screening instruments.
- Train staff on the importance of depression screenings and recognizing the risk factors for depression.
- Work with a care team to coordinate follow-up care for persons with a positive screening.
- Ensure all services conducted during the visit are coded appropriately, including the depression screening LOINC codes.
- Coordinate file submissions to the health plan that include EHR data.

Description	Codes*
Behavioral Health Encounter	CPT: 90791, 90792, 90832–90839, 90845–90849, 90853, 90865–90869, 90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493
Depression Case Management Encounter That Documents Assessment for Symptoms of Depression or a Diagnosis of Depression or Other Behavioral Health	CPT: 99366, 99492–99494 HCPCS: G0512, T1016, T1017, T2022, T2023
Follow Up Visit With a Diagnosis of Depression or Other Behavioral Health Condition	CPT: 98000–98016, 98960–98962, 98966–98968, 98970–98972, 98980, 98981, 99078, 99202–99205, 99211–99215, 99242–99245, 99341–99342, 99344–99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99421–99423, 99441–99443, 99457, 99458, 99483 HCPCS: G0071, G0463, G2010, G2012, G2250–G2252, T1015 ICD-10: F01.511, F01.518, F06.4, F10.180, F10.280, F10.980, F11.188, F11.288, F11.988, F12.180, F12.280, F12.980, F13.180, F13.280, F13.980, F13.180, F13.280, F13.980, F14.180, F14.280, F14.980, F15.180, F15.280, F15.980, F16.180, F16.280, F16.980, F18.180, F18.280, F18.980, F20.0–F20.3, F20.5, F20.81, F20.89, F20.9, F21–F24, F25.0, F25.1, F25.8, F25.9, F28–F29, F30.10–F30.13, F30.2–F30.4, F30.8, F30.9, F31.0, F31.10–F31.13, F31.2, F31.30–F31.32, F31.4, F31.5, F31.60–F31.64, F31.70–F31.78, F31.81, F31.89, F32.0–F32.5, F32.81, F32.89, F32.9, F32.A, F33.0–F33.3, F33.40–F33.42, F33.8, F33.9, F34.0, F34.1, F34.81, F34.89, F34.9, F39, F40.00–F40.02, F40.10, F40.11, F40.210, F40.218, F40.220, F40.228, F40.230–F40.233, F40.240–F40.243, F40.248, F40.290, F20.291, F40.298, F40.8–F41.1, F41.3, F41.8, F41.9, F42.2–F42.4, F42.8, F42.9, F43.0, F43.10–F43.12, F43.20–F43.25, F43.29, F43.81, F43.89, F43.9, F44.89, F45.21, F51.5, F53.0, F53.1, F60.0–F60.7, F60.81, F60.89, F60.9, F63.0–F63.3, F63.81, F63.89, F63.9, F69.10–F68.13, F68.8, F68.A, F84.0, F8.2, F84.3, F84.5, F84.8, F84.9, F90.0–F90.2, F90.8, F90.9, F91.0–F91.3, F91.8, F91.9, F93.0, F93.8, F93.9, F94.0–F94.2, F94.8, F94.9, O90.6, O99.340–O99.345

(continued)



(DSF-E) Depression Screening and Follow-Up for Adolescents and Adults *(continued)*

Description	Codes*
Hospice Encounter With a Diagnosis of Depression or Other Behavioral Health Condition	ICD-10: F01.511, F01.518, F06.4, F10.180, F10.280, F10.980, F11.188, F11.288, F11.988, F12.180, F12.280, F12.980, F13.180, F13.280, F13.980, F13.180, F13.280, F13.980, F14.180, F14.280, F14.980, F15.180, F15.280, F15.980, F16.180, F16.280, F16.980, F18.180, F18.280, F18.980, F20.0-F20.3, F20.5, F20.81, F20.89, F20.9, F21-F24, F25.0, F25.1, F25.8, F25.9, F28-F29, F30.10-F30.13, F30.2-F30.4, F30.8, F30.9, F31.0, F31.10-F31.13, F31.2, F31.30-F31.32, F31.4, F31.5, F31.60-F31.64, F31.70-F31.78, F31.81, F31.89, F32.0-F32.5, F32.81, F32.89, F32.9, F32.A, F33.0-F33.3, F33.40-F33.42, F33.8, F33.9, F34.0, F34.1, F34.81, F34.89, F34.9, F39, F40.00-F40.02, F40.10, F40.11, F40.210, F40.218, F40.220, F40.228, F40.230-F40.233, F40.240--F40.243, F40.248, F40.290, F20.291, F40.298, F40.8-F41.1, F41.3, F41.8, F41.9, F42.2-F42.4, F42.8, F42.9, F43.0, F43.10-F43.12, F43.20-F43.25, F43.29, F43.81, F43.89, F43.9, F44.89, F45.21, F51.5, F53.0, F53.1, F60.0-F60.7, F60.81, F60.89, F60.9, F63.0-F63.3, F63.81, F63.89, F63.9, F69.10-F68.13, F68.8, F68.A, F84.0, F8.2, F84.3, F84.5, F84.8, F84.9, F90.0-F90.2, F90.8, F90.9, F91.0-F91.3, F91.8, F91.9, F93.0, F93.8, F93.9, F94.0-F94.2, F94.8, F94.9, O90.6, O99.340-O99.345
Exercise Counseling	ICD-10: Z71.82
Dispensed Antidepressant Medication	

*Codes subject to change.



(FUA) Follow-Up After Emergency Department Visit for Substance Use Disorder (SUD)

Applicable Foster Care Measure

Measure evaluates the percentage of ED visits among persons 13 years of age and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose for which there was a follow-up.

Measure is based on ED visits; persons may appear in a measure sample more than once. Each ED visit requires a separate follow-up.

Two rates are reported:

1 Discharges for which the person received follow-up within 30 days of discharge.

A follow-up visit or a pharmacotherapy dispensing event within 30 days after the ED visit (31 total days). Include visits and pharmacotherapy events that occur on the date of the ED visit.

2 Discharges for which the person received follow-up within seven days of discharge.

A follow-up visit or a pharmacotherapy dispensing event within seven days after the ED visit (eight total days). Include visits and pharmacotherapy events that occur on the date of the ED visit.

(continued)



(FUA) Follow-Up After Emergency Department Visit for Substance Use Disorder (SUD) *(continued)*

Tips

- Offer virtual, telehealth, and phone visits.
- Maintain appointment availability in your practice for persons, and schedule follow-up appointments before the person leaves the office.
- Discuss the benefits of seeing a primary or specialty provider.
- Offer mutual help options like case management, peer recovery support, harm reduction, 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), or other community support groups.
- Reach out proactively within 24 hours if the person does not keep scheduled appointment to schedule another.

The visit can be with any practitioner if the claim includes a diagnosis of SUD (e.g., F10.xx–F19.xx) or drug overdose (e.g., T40–T43, T51). If the visit occurs with a mental health provider, the claim does not have to include the SUD or drug overdose diagnosis.

Description	Codes*
Outpatient Visit with any Diagnosis of SUD or Drug Overdose	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255, 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245, 99341, 99342, 99344, 99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99492–99494, 99510</p> <p>HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2013, H2015, H2013–H2020, T1015</p> <p>POS: 03, 05, 07, 09, 11–20, 22, 33, 49, 50, 71–72</p>
Intensive Outpatient Encounter or Partial Hospitalization with any Diagnosis of SUD or Drug Overdose	<p>CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485</p>
Non-residential Substance Abuse Treatment Facility with any Diagnosis of SUD or Drug Overdose	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 57, 58</p>
Community Mental Health Center Visit with any Diagnosis of SUD or Drug Overdose	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 53</p>

(continued)



(FUA) Follow-Up After Emergency Department Visit for Substance Use Disorder (SUD) *(continued)*

Description	Codes*
Peer Support Service with any Diagnosis of SUD or Drug Overdose	HCPCS: G0140, G0177, H0024, H0025, H0038–H0040, H0046, H2014, H2023, S9445, T1012, T1016
Opioid Treatment Service That Bills Monthly or Weekly with any Diagnosis of SUD or Drug Overdose	HCPCS: G2086, G2087, G2071, G8074–G2077, G2080
Telehealth Visit with any Diagnosis of SUD or Drug Overdose	CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255 POS: 02, 10
Telephone Visit with any Diagnosis of SUD or Drug Overdose	CPT: 98966–98968, 99441–99443
E-Visit or Virtual Check In with any Diagnosis of SUD or Drug Overdose	CPT: 98970–98972, 98980, 98981, 99422–99444, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250–G2252
Substance Use Disorder Services	CPT: 99408, 99409 HCPCS: G0396, G0397, H0001, H0005, H0015, H0016, H0022, H0047, H0050, H2035, H2036, H0006, H0028, T1006, T1012
Behavioral Health Screening or Assessment for SUD or Mental Health Disorders	CPT: 99408, 99409 HCPCS: G0396, G0397, G0442, G2011, H0001, H0002, H0031, H0049
Pharmacotherapy Dispensing Event or Medication Treatment Event	Medications: Disulfiram (oral), Naltrexone (oral and injectable), acamprosate (oral; delayed-release tablet), buprenorphine (implant, injection, or sublingual tablet), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) HCPCS: G2069, G2070, G2072, G2073, H0020, H0033, J0570–J0575, J0577, J0578, J2315, Q9991, Q9992, S0109

*Codes subject to change.





(FUH) Follow-Up After Hospitalization for Mental Illness

Applicable Foster Care Measure

Measure evaluates the percentage of discharges for persons six years of age and older who were hospitalized for a principal diagnosis of mental illness, or any diagnosis of intentional self-harm, and had a mental health follow-up service.

Two rates are reported:

- 1 Discharges for which the person received **follow-up within 30 days after discharge**.
- 2 Discharges for which the person received **follow-up within seven days after discharge**.



Tips

- Schedule follow-up appointments prior to discharge and include the date and time on discharge instructions.
- Offer telehealth, and phone visits.
- Reach out proactively to assist in scheduling/rescheduling appointments within the required timeframes.
- Partner with the health plan to address social determinants, health equity, and quality care.
- Address comorbidities and integrate care with peer support and psychiatric collaborative care models.
- Submit applicable codes.

Description	Codes*
Outpatient Visit with a Mental Health Provider or With Any Diagnosis of a Mental Health Disorder	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255, 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245, 99341, 99342, 99344, 99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99492–99494, 99510 POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013–H2020, T1015
Visit Setting Unspecified for Intensive Outpatient Encounter or Partial Hospitalization	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255 POS: 52
Partial Hospitalization/ Intensive Outpatient	HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485

(continued)



(FUH) Follow-Up After Hospitalization for Mental Illness *(continued)*

Description	Codes*
Community Mental Health Center Visit	<p>CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 98960–98962, 99078, 99202–99205, 99211–99215, 99221–99223, 99231–99233, 99238, 99239, 99242–99245, 99252–99255, 99341, 99342, 99344, 99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99494, 99510</p> <p>HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013–H2020, T1015</p> <p>POS: 53</p>
Electroconvulsive Therapy	<p>CPT: 90870</p> <p>POS: 24, 52, 53</p>
Peer Support Services or With Any Diagnosis of a Mental Health Disorder	<p>HCPCS: G0140, G0177, H0024, H0025, H0038–H0040, H0046, H2014, H2023, S9445, T1012, T1013</p>
Psychiatric Residential	<p>CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 56</p>
Telehealth Visit With a Mental Health Provider or Any Diagnosis of a Mental Health Disorder	<p>CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 02, 10</p>
Transitional Care Management	<p>CPT: 99495, 99496</p>
Telephone Visit With a Mental Health Provider or Any Diagnosis of a Mental Health Disorder	<p>CPT: 98966–98968, 99441–99443</p>
Psychiatric Collaborative Care Management With a Mental Health Provider or Any Diagnosis of a Mental Health Disorder	<p>CPT: 99492–99494</p> <p>HCPCS: G0512</p>

*Codes subject to change.





(FUI) Follow-Up After High-Intensity Care for Substance Use Disorder (SUD)

Measure evaluates the percentage of acute inpatient hospitalizations, residential treatment, or withdrawal management visits for a diagnosis of substance use disorder among persons 13 years of age and older that result in a follow-up visit or service for substance use disorder during the measurement period.

- ✓ For an acute inpatient discharge or residential treatment discharge, or for withdrawal management that occurred during an acute inpatient stay or residential treatment stay, the episode date is the date of discharge.
- ✓ For direct transfers, the episode date is the discharge date from the transfer admission.
- ✓ For withdrawal management (other than withdrawal management that occurred during an acute inpatient stay or residential treatment stay), the episode date is the date of service.

Two rates are reported:

- 1 The percentage of visits or discharges for which the person received follow-up for substance use disorder **within the 30 days after the visit or discharge.**
- 2 The percentage of visits or discharges for which the person received follow-up for substance use disorder **within the seven days after the visit or discharge.**

Note: Follow up does not include withdrawal management.

Tips

- Offer virtual, telehealth, and phone visits.
- Maintain appointment availability in your practice for persons and schedule follow-up appointments before the person leaves the office.
- Offer mutual help options like case management, peer recovery support, harm reduction, 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), or other community support groups.
- Reach out proactively within 24 hours if the person does not keep scheduled appointment to schedule another.

The claim should include a principal diagnosis of substance use disorder (e.g., applicable code F10.10–F19.29)

(continued)



(FUI) Follow-Up After High-Intensity Care for Substance Use Disorder (SUD) *(continued)*

Description	Codes*
Outpatient Visit with a Diagnosis of SUD	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 98000–98007, 99221–99223, 99231–99233, 99238, 99239, 99252–99255, 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245, 99341–99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99492–99494, 99510</p> <p>HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, G0560, H0002, H0004, H0031, H0034, H0036, H0037, H2000, H2010, H2011, H2013–H2020, H0039, H0040, T1015</p> <p>POS: 03, 05, 07, 09, 11–20, 22, 33, 49, 50, 71–72</p>
Intensive Outpatient Encounter or Partial Hospitalization with a Diagnosis of SUD	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485</p> <p>POS: 52</p>
Non-residential Substance Abuse Treatment Facility with a Diagnosis of SUD	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 57, 58</p>
Community Mental Health Center Visit with a Diagnosis of SUD	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 53</p>
Telehealth Visit with a Diagnosis of SUD	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 02, 10</p>
Substance Use Disorder Services with a Diagnosis of SUD	<p>CPT: 99408, 99409</p> <p>HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012</p>
Opioid Treatment Service that Bills Monthly or Weekly with a Diagnosis of SUD	<p>HCPCS: G2071, G2074–G2077, G2080, G2086, G2087</p>
Residential Behavioral Health Treatment with a Diagnosis of SUD	<p>HCPCS: H0017, H0018, H0019, T2048</p>
Substance Use Disorder Counseling and Surveillance	<p>ICD-10: Z71.41, Z71.51</p>
Telephone Visit with a Diagnosis of SUD	<p>CPT: 98966–98968, 99441–99443</p>

(continued)



(FUI) Follow-Up After High-Intensity Care for Substance Use Disorder (SUD) *(continued)*

Description	Codes*
E-Visit or Virtual Check in with a Diagnosis of SUD	CPT: 98970–98972, 98980, 98981, 99421–99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250–G2252
Pharmacotherapy Dispensing Event or Medication Treatment Event	Medications: Disulfiram (oral), Naltrexone (oral and injectable), acamprosate (oral; delayed-release tablet), buprenorphine (implant, injection, or sublingual tablet), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) HCPCS: G2069, G2070, G2072, G2073, H0020, H0033, J0570–J0575, J0577, J0578, J2315, Q9991, Q9992, S0109
Peer Support Services with a Diagnosis of SUD	HCPCS: G0140, G0177, H0024, H0025, H0038–H0040, H0046, H2014, H2023, S9445, T1012, T1016, T1017

*Codes subject to change.



(FUM) Follow-Up After Emergency Department Visit for Mental Illness

Applicable Foster Care Measure

Measure evaluates the percentage of ED visits for persons six years of age and older with a principal diagnosis of mental illness, or any diagnosis of intentional self-harm, and had a mental health follow-up service during the measurement period.

Two rates are reported:

- 1 The percentage of ED visits for which the person received follow-up **within 30 days of the ED visit (31 total days)**.
- 2 The percentage of ED visits for which the person received follow-up **within seven days of the ED visit (eight total days)**.



Tips

- Offer virtual, telehealth, and phone visits.
- Maintain appointment availability in your practice for persons and schedule follow-up appointments before the person leaves the office.
- Discuss the benefits of seeing a primary or specialty provider and appropriate ED utilization.
- Partner with the health plan to address social determinants, health equity, and quality care.

The claim should include a diagnosis of mental health disorder.

(continued)



(FUM) Follow-Up After Emergency Department Visit for Mental Illness *(continued)*

Description	Codes*
Outpatient Visit with any Diagnosis of a Mental Health Disorder	<p>CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 98000–98007, 99221–99223, 99231–99233, 99238, 99239, 99252–99255, 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245, 99341–99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99492–99494, 99510</p> <p>HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, G0560, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013–H2020, T1015</p> <p>POS: 03, 05, 07, 09, 11–20, 22, 33, 49, 50, 71–72</p>
Intensive Outpatient Encounter or Partial Hospitalization with any Diagnosis of a Mental Health Disorder	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485</p> <p>POS: 52</p>
Community Mental Health Center Visit	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 53</p>
Electroconvulsive Therapy	<p>CPT: 90780</p> <p>POS: 24, 52, 53</p>
Telehealth Visit with any Diagnosis of a Mental Health Disorder	<p>CPT: 90791, 90792, 90832, 90833, 90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 02, 10</p>
Telephone Visit with any Diagnosis of a Mental Health Disorder	<p>CPT: 98966–98968, 99441–99443</p>
E-Visit or Virtual Check in with any Diagnosis of a Mental Health Disorder	<p>CPT: 98970–98972, 98980, 98981, 99421–99423, 99457, 99458</p> <p>HCPCS: G0071, G2010, G2012, G2250–G2252</p>
Peer Support Services with any Diagnosis of a Mental Health Disorder	<p>HCPCS: G0140, G0177, H0024, H0025, H0038–H0040, H0046, H2014, H2023, S9445, T1012, T1016</p>
Psychiatric Collaborative Care Management	<p>CPT: 99492–99494</p> <p>HCPCS: G0140, T1017</p>
Psychiatric Residential Treatment	<p>CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255</p> <p>POS: 56</p>

*Codes subject to change.





(HDO) Use of Opioids at High Dosage

Measures the percentage of persons 18 years of age and older who received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] ≥ 90) for ≥ 15 days during the measurement period.

Decreased score indicates improvement.

Type of Opioid	Medication Lists	Strength	MME Conversion Factor
Benzhydrocodone	• Acetaminophen Benzhydrocodone 4.08 mg Medications List	4.08 mg	1.2
	• Acetaminophen Benzhydrocodone 6.12 mg Medications List	6.12 mg	
	• Acetaminophen Benzhydrocodone 8.16 mg Medications List	8.16 mg	
Butorphanol	• Butorphanol 10 MGPML Medications List	10 mg	7
Codeine	• Codeine Sulfate 15 mg Medications List	15 mg	0.15
	• Codeine Sulfate 30 mg Medications List	30 mg	
	• Codeine Sulfate 60 mg Medications List	60 mg	
Codeine	• Acetaminophen Codeine 2.4 MGPML Medications List	2.4 mg	0.15
	• Acetaminophen Codeine 15 mg Medications List	15 mg	
	• Acetaminophen Codeine 30 mg Medications List	30 mg	
	• Acetaminophen Codeine 60 mg Medications List	60 mg	
Codeine	• Acetaminophen Butalbital Caffeine Codeine 30 mg Medications List	30 mg	0.15
Codeine	• Aspirin Butalbital Caffeine Codeine 30 mg Medications List	30 mg	0.15
Codeine	• Aspirin Carisoprodol Codeine 16 mg Medications List	16 mg	0.15
Dihydrocodeine	• Acetaminophen Caffeine Dihydrocodeine 16 mg Medications List	16 mg	0.25
Fentanyl Buccal or Sublingual Tablet, Transmucosal Lozenge (mcg) ¹	• Fentanyl 100 mcg Medications List	100 mcg	0.13
	• Fentanyl 200 mcg Medications List	200 mcg	
	• Fentanyl 300 mcg Medications List	300 mcg	
	• Fentanyl 400 mcg Medications List	400 mcg	
	• Fentanyl 600 mcg Medications List	600 mcg	
	• Fentanyl 800 mcg Medications List	800 mcg	
	• Fentanyl 1200 mcg Medications List	1200 mcg	
	• Fentanyl 1600 mcg Medications List	1600 mcg	
Fentanyl Oral Spray (mcg) ²	• Fentanyl 100 MCGPS Oral Medications List	100 mcg	0.18
	• Fentanyl 200 MCGPS Oral Medications List	200 mcg	
	• Fentanyl 400 MCGPS Oral Medications List	400 mcg	
	• Fentanyl 600 MCGPS Oral Medications List	600 mcg	
	• Fentanyl 800 MCGPS Oral Medications List	800 mcg	

(continued)



(HDO) Use of Opioids at High Dosage *(continued)*

Type of Opioid	Medication Lists	Strength	MME Conversion Factor
Fentanyl Nasal Spray (mcg) ³	• Fentanyl 100 MCGPS Nasal Medications List	100 mcg	0.16
	• Fentanyl 300 MCGPS Nasal Medications List	300 mcg	
	• Fentanyl 400 MCGPS Nasal Medications List	400 mcg	
Fentanyl Transdermal Film/Patch (mcg/hr) ⁴	• Fentanyl 12 MCGPH Medications List	12 mcg	7.2
	• Fentanyl 25 MCGPH Medications List	25 mcg	
	• Fentanyl 37.5 MCGPH Medications List	37.5 mcg	
	• Fentanyl 50 MCGPH Medications List	50 mcg	
	• Fentanyl 62.5 MCGPH Medications List	62.5 mcg	
	• Fentanyl 75 MCGPH Medications List	75 mcg	
	• Fentanyl 87.5 MCGPH Medications List	87.5 mcg	
Hydrocodone	• Hydrocodone 10 mg Medications List	10 mg	1
	• Hydrocodone 15 mg Medications List	15 mg	
	• Hydrocodone 20 mg Medications List	20 mg	
	• Hydrocodone 30 mg Medications List	30 mg	
	• Hydrocodone 40 mg Medications List	40 mg	
	• Hydrocodone 50 mg Medications List	50 mg	
	• Hydrocodone 60 mg Medications List	60 mg	
	• Hydrocodone 80 mg Medications List	80 mg	
	• Hydrocodone 100 mg Medications List	100 mg	
Hydrocodone	• Acetaminophen Hydrocodone .5 MGPML Medications List	.5 mg .67 mg	1
	• Acetaminophen Hydrocodone .67 MGPML Medications List	2.5 mg 5 mg	
	• Acetaminophen Hydrocodone 2.5 mg Medications List	7.5 mg	
	• Acetaminophen Hydrocodone 5 mg Medications List	10 mg	
	• Acetaminophen Hydrocodone 7.5 mg Medications List		
	• Acetaminophen Hydrocodone 10 mg Medications List		
Hydrocodone	• Hydrocodone Ibuprofen 2.5 mg Medications List	2.5 mg	1
	• Hydrocodone Ibuprofen 5 mg Medications List	5 mg	
	• Hydrocodone Ibuprofen 7.5 mg Medications List	7.5 mg	
	• Hydrocodone Ibuprofen 10 mg Medications List	10 mg	
Hydromorphone	• Hydromorphone 1 MGPML Medications List	1 mg	4
	• Hydromorphone 2 mg Medications List	2 mg	
	• Hydromorphone 3 mg Medications List	3 mg	
	• Hydromorphone 4 mg Medications List	4 mg	
	• Hydromorphone 8 mg Medications List	8 mg	
	• Hydromorphone 12 mg Medications List	12 mg	
	• Hydromorphone 16 mg Medications List	16 mg	
• Hydromorphone 32 mg Medications List	32 mg		

(continued)



(HDO) Use of Opioids at High Dosage *(continued)*

Type of Opioid	Medication Lists	Strength	MME Conversion Factor
Levorphanol	• Levorphanol 2 mg Medications List	2 mg	11
	• Levorphanol 3 mg Medications List	3 mg	
Meperidine	• Meperidine 10 MGPML Medications List	10 mg	0.1
	• Meperidine 50 mg Medications List	50 mg	
	• Meperidine 100 mg Medications List	100 mg	
Methadone ⁵	• Methadone 1 MGPML Medications List	1 mg	3
	• Methadone 2 MGPML Medications List	2 mg	
	• Methadone 5 mg Medications List	5 mg	
	• Methadone 10 mg Medications List	10 mg	
	• Methadone 10 MGPML Medications List	10 mg	
	• Methadone 40 mg Medications List	40 mg	
Morphine	• Morphine 2 MGPML Medications List	2 mg	1
	• Morphine 4 MGPML Medications List	4 mg	
	• Morphine 5 mg Medications List	5 mg	
	• Morphine 10 mg Medications List	10 mg	
	• Morphine 15 mg Medications List	15 mg	
	• Morphine 20 MGPML Medications List	20 mg	
	• Morphine 20 mg Medications List	20 mg	
	• Morphine 30 mg Medications List	30 mg	
	• Morphine 40 mg Medications List	40 mg	
	• Morphine 45 mg Medications List	45 mg	
	• Morphine 50 mg Medications List	50 mg	
	• Morphine 60 mg Medications List	60 mg	
	• Morphine 75 mg Medications List	75 mg	
	• Morphine 80 mg Medications List	80 mg	
	• Morphine 90 mg Medications List	90 mg	
	• Morphine 100 mg Medications List	100 mg	
	• Morphine 120 mg Medications List	120 mg	
• Morphine 200 mg Medications List	200 mg		
Opium	• Belladonna Opium 30 mg Medications List	30 mg	1
	• Belladonna Opium 60 mg Medications List	60 mg	
Oxycodone	• Oxycodone 1 MGPML Medications List	1 mg	1.5
	• Oxycodone 5 mg Medications List	5 mg	
	• Oxycodone 7.5 mg Medications List	7.5 mg	
	• Oxycodone 9 mg Medications List	9 mg	
	• Oxycodone 10 mg Medications List	10 mg	
	• Oxycodone 13.5 mg Medications List	13.5 mg	
	• Oxycodone 15 mg Medications List	15 mg	
	• Oxycodone 18 mg Medications List	18 mg	

(continued)



(HDO) Use of Opioids at High Dosage *(continued)*

Type of Opioid	Medication Lists	Strength	MME Conversion Factor
Oxycodone	• Oxycodone 20 mg Medications List	20 mg	1.5
	• Oxycodone 20 MGPML Medications List	20 mg	
	• Oxycodone 27 mg Medications List	27 mg	
	• Oxycodone 30 mg Medications List	30 mg	
	• Oxycodone 36 mg Medications List	36 mg	
	• Oxycodone 40 mg Medications List	40 mg	
	• Oxycodone 60 mg Medications List	60 mg	
	• Oxycodone 80 mg Medications List	80 mg	
Oxycodone	• Acetaminophen Oxycodone 1 MGPML Medications List	1 mg	1.5
	• Acetaminophen Oxycodone 2 MGPML Medications List	2 mg	
	• Acetaminophen Oxycodone 2.5 mg Medications List	2.5 mg	
	• Acetaminophen Oxycodone 5 mg Medications List	5 mg	
	• Acetaminophen Oxycodone 7.5 mg Medications List	7.5 mg	
	• Acetaminophen Oxycodone 10 mg Medications List	10 mg	
Oxycodone	• Aspirin Oxycodone 4.84 mg Medications List	4.84 mg	1.5
Oxycodone	• Ibuprofen Oxycodone 5 mg Medications List	5 mg	1.5
Oxymorphone	• Oxymorphone 5 mg Medications List	5 mg	3
	• Oxymorphone 7.5 mg Medications List	7.5 mg	
	• Oxymorphone 10 mg Medications List	10 mg	
	• Oxymorphone 15 mg Medications List	15 mg	
	• Oxymorphone 20 mg Medications List	20 mg	
	• Oxymorphone 30 mg Medications List	30 mg	
	• Oxymorphone 40 mg Medications List	40 mg	
	Pentazocine	• Naloxone Pentazocine 50 mg Medications List	
Tapentadol	• Tapentadol 50 mg Medications List	50 mg	0.4
	• Tapentadol 75 mg Medications List	75 mg	
	• Tapentadol 100 mg Medications List	100 mg	
	• Tapentadol 150 mg Medications List	150 mg	
	• Tapentadol 200 mg Medications List	200 mg	
	• Tapentadol 250 mg Medications List	250 mg	
Tramadol	• Tramadol 5 MGPML Medications List	5 mg	0.1
	• Tramadol 50 mg Medications List	50 mg	
	• Tramadol 100 mg Medications List	100 mg	
	• Tramadol 150 mg Medications List	150 mg	
	• Tramadol 200 mg Medications List	200 mg	
	• Tramadol 300 mg Medications List	300 mg	
Tramadol	• Acetaminophen Tramadol 37.5 mg Medications List	37.5 mg	0.1





(IET) Initiation and Engagement of Substance Use Disorder (SUD) Treatment

Applicable Foster Care Measure

Time frame for measure: (to capture episodes) Nov. 15 of the year prior to the measurement period through Nov. 14 of the measurement period.

Measure evaluates the percentage of adolescent and adult persons with a new episode of substance use disorder (SUD) episodes during the measurement period that result in treatment initiation and engagement.

Two rates are reported:

- 1 Initiation of SUD Treatment:** percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth, or medication treatment **within 14 days**.
- 2 Engagement of SUD Treatment:** percentage of new SUD episodes that have evidence of treatment engagement **within 34 days of initiation**.



Tips

- Complete a comprehensive exam before diagnosing; co-existing disorders are not uncommon and can undermine effectiveness and adherence to treatment.
- Develop working alliances with specialists in substance use disorders for persons who would benefit from specialty care.
- Explain the importance of a follow-up to your persons.
- Schedule an initial follow-up appointment within 14 days.
- Reschedule persons as soon as possible if they do not keep initial appointments.
- Use telehealth where appropriate.
- Offer mutual help options like case management, peer recovery support, harm reduction, 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), or other community support groups.
- Maintain appointment availability in your practice for persons and schedule follow-up appointments before the person leaves the office.
- Submit applicable codes.

A diagnosis of Alcohol, Opioid, or Other Drug Abuse and Dependence with one of the following:

Description	Codes*
Acute or Nonacute Inpatient Admission	UBREV: 0100–0101, 0110–0114, 0116–0124, 0126–0134, 0136–0144, 0146–0154, 0156–0160, 0164, 0167, 0169–0174, 0179, 0190–0194, 0199–0204, 0206–0214, 0219, 1000–1002
Outpatient Visit	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99252–99255 with POS 03, 05, 07, 09, 11–20, 22, 33, 49, 50, 71, 72

(continued)



(IET) Initiation and Engagement of Substance Use Disorder (SUD) Treatment *(continued)*

Description	Codes*
Behavioral Health Outpatient Visit	CPT: 98000–98007, 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245, 99341, 99342, 99344, 99345, 99347, 99348, 99350, 99381–99387, 99391–99397, 99401–99404, 99411–99412, 99483, 99492–99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, G0560, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013–H2020, T1015
Intensive Outpatient Encounter or Partial Hospitalization	CPT: 90791–90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875–90876, 99221–99223, 99231–99233, 99238–99239, 99251–99255 with POS 52 or G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485
Non-residential Substance Abuse Treatment Facility	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875–90876, 99221–99223, 99231–99233, 99238–99239, 99251–99255 with POS 57, 58
An Outpatient Visit at a Community Mental Health Center	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875–90876, 99221–99223, 99231–99233, 99238–99239, 99251–99255 with POS 53
Telehealth Visit	CPT: 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90875–90876, 99221–99223, 99231–99233, 99238–99239, 99251–99255 with POS 02, 10
A Substance Use Disorder Service	CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012
A Substance Use Disorder Counseling and Surveillance	ICD-10: Z71.41, Z71.51
Telephone Visit	CPT: 98966–98968, 99441–99443
An E-Visit or Virtual Check-In Visit	CPT: 98969–98972, 98980, 98981, 99421–99444, 99457, 99458 HCPCS: G0071, G2010, G2012, G2061–G2063, G2250–H2252
Opioid Treatment Service that Bills Monthly or Weekly	HCPCS: G2071, G2074–G2077, G2080, G2086, G2087
An Alcohol Use Disorder Medication Dispensing Event (For Alcohol Cohort)	Disulfiram (oral), naltrexone (oral and injectable), acamprosate (oral and delayed-release tablet)
An Opioid Use Disorder Medication Dispensing Event (For Opioid Use Cohort)	Naltrexone (oral and injectable), buprenorphine (sublingual tablet, injection, implant), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) HCPCS: G2069, G2070, G2072, G2073, H0020, H0033, J0570–J0575, J2315, Q9991, Q9992, S0109, G2067–G2070, G2072, G2073

*Codes subject to change.

(continued)



(IET) Initiation and Engagement of Substance Use Disorder (SUD) Treatment *(continued)*

Medication Treatment Events:

- ✓ **Alcohol Use Disorder Treatment Medications:** Disulfiram (oral), naltrexone (oral and injectable), acamprosate (oral; delayed-release tablet).
- ✓ **Opioid Use Disorder Treatment Medications:** Naltrexone (oral and injectable), buprenorphine (sublingual tablet, injection, and implant), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film).
- ✓ Methadone is not included on the medication lists for this measure. Methadone for OUD administered or dispensed by federally certified opioid treatment programs (OTP) is billed on a medical claim. A pharmacy claim for methadone would be indicative of treatment for pain rather than OUD.



(PDS-E) Postpartum Depression Screening and Follow-Up

Measure evaluates the percentage of deliveries in which persons were screened for clinical depression **during the postpartum period**, and if screened positive, received follow-up care.

Two rates are reported:

- 1 Depression Screening.** The percentage of deliveries in which persons were screened for clinical depression using a standardized instrument during the postpartum period (7-84 days following the date of delivery).
- 2 Follow-Up on Positive Screen.** The percentage of deliveries in which persons received follow-up care on or up to 30 days after the date of the first positive depression screen finding (31 total days).

Note: A LOINC code submission via flat file is required to be adherent for the depression screening numerator.



Tips

- Use age-appropriate screening instruments.
- If there is a positive screen resulting from a PHQ-2 score, documentation of a negative finding from a PHQ-9 performed on the same day qualifies as evidence of follow up.
- Train staff on the importance of depression screenings and recognizing the risk factors for depression during and post pregnancy.
- Develop a workflow that includes utilizing a standardized instrument for depression screenings at every visit.
- Ask your provider relations representative about ways to submit data to the health plan directly from your EHR/EMR.
- Document follow-up on positive screen on or up to 30 days after the first positive screen.

(continued)



(PDS-E) Postpartum Depression Screening and Follow-Up *(continued)*

Depression Screening instrument: A standard assessment instrument that has been normalized and validated for the appropriate person population. Eligible screening instruments with thresholds for positive findings for numerator 1 include:

Instruments for Adolescents (≤ 17 years)	Total Score LOINC Codes	Positive Finding
Patient Health Questionnaire (PHQ-9) [®]	44261-6	Total score ≥ 10
Patient Health Questionnaire Modified for Teens (PHQ-9M) [®]	89204-2	Total score ≥ 10
Patient Health Questionnaire-2 (PHQ-2) [®]	55758-7	Total score ≥ 3
Beck Depression Inventory-Fast Screen (BDI-FS) [®]	89208-3	Total score ≥ 8
Center for Epidemiologic Studies Depression Scale—Revised (CESD-R)	89205-9	Total score ≥ 17
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥ 10
PROMIS Depression	71965-8	Total score ≥ 60
Instruments for Adults (18+ years)	Total Score LOINC Codes	Positive Finding
Patient Health Questionnaire (PHQ-9) [®]	44261-6	Total score ≥ 10
Patient Health Questionnaire-2 (PHQ-2) [®]	55758-7	Total score ≥ 3
Beck Depression Inventory-Fast Screen (BDI-FS) [®]	89208-3	Total score ≥ 8
Beck Depression Inventory (BDI-II)	89209-1	Total score ≥ 20
Center for Epidemiologic Studies Depression Scale—Revised (CESD-R)	89205-9	Total score ≥ 17
Duke Anxiety—Depression Scale (DUKE-AD) [®]	90853-3	Total score ≥ 30
Edinburgh Postnatal Depression Scale (EPDS)	99046-5	Total score ≥ 10
My Mood Monitor (M-3) [®]	71777-7	Total score ≥ 5
PROMIS Depression	71965-8	Total score ≥ 60
PROMIS Emotional Distress-Depression-Short Form	77861-3	Total score ≥ 60
Clinically Useful Depression Outcome Scale (CUDOS)	90221-3	Total score ≥ 31

- ✓ If the depression screening is positive, the person must receive follow-up care on or up to 30 days after the date of the first positive screening.

(continued)



(PDS-E) Postpartum Depression Screening and Follow-Up *(continued)*

Description	Codes*
An Outpatient, Telephone, E-visit, or Virtual Check-In Follow-Up Visit with a Diagnosis of Depression or Other Behavioral Health Condition	<p>UBREV: 0510, 0513, 0516, 0517, 0519–0523, 0526–0529, 0982, 0983</p> <p>CPT: 98960–98962, 98966–98968, 98970–98972, 98980, 98981, 99078, 99202–99205, 99211–99215, 99242–99245, 99341, 99342, 99344, 99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99421–99423, 99441–99443, 99457, 99458, 99483</p> <p>HCPCS: G0071, G0463, G2010, G2012, G2250–G2252, T1015</p>
Depression Case Management Encounter that Documents Assessment for Symptoms of Depression (i.e., SNOMED) or a Diagnosis of Depression or Other Behavioral Health Condition	<p>CPT: 99366, 99492–99494</p> <p>HCPCS: G0512, T1016, T1017, T2022, T2023</p>
Behavioral Health Encounter, Including Assessment, Therapy, Collaborative Care, or Medication Management	<p>CPT: 90791, 90792, 90832–90834, 90836–90839, 90845–90847, 90849, 90853, 90865, 90867–90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493</p> <p>HCPCS: G0155, G0176, G0177, G0409–G0411, G0511, G0512, H0002, H0004, H0031, H0034–H0037, H0039, H0040, H2000, H2001, H2010–H2020, S0201, S9480, S9484, S9485</p> <p>UBREV: 0900–0905, 0907, 0911–0917, 0919</p>
Exercise Counseling	ICD-10: Z71.82
Dispensed Antidepressant Medication	
Documentation of an additional depression screening on a full-length instrument (i.e., PHQ-9 [®]) indicating either no depression or no symptoms that require follow-up (i.e., negative screen) on the same day as a positive screen on a brief screening instrument (i.e., PHQ-2 [®]).	

*Codes subject to change.





(PND-E) Prenatal Depression Screening

Measure evaluates the percentage of deliveries with at least 37 weeks of gestation in which persons were screened for clinical depression while pregnant and, if screened positive, received follow-up care during the measurement period.

Two rates are reported:

- 1 Depression Screening.** The percentage of deliveries in which persons were screened for clinical depression during pregnancy using a standardized instrument.
- 2 Follow-Up on Positive Screen.** The percentage of deliveries in which persons received follow-up care within 30 days of a positive depression screen finding.

Note: Applicable LOINC codes are required for numerator 1 (Depression Screening).

Depression Screening instrument: A standard assessment instrument that has been normalized and validated for the appropriate person population. Eligible screening instruments with thresholds for positive findings include:

Instruments for Adolescents (≤17 years)	Positive Finding	LOINC Code (Required for numerator 1)
Patient Health Questionnaire (PHQ-9) [®]	Total score ≥10	44261-6
Patient Health Questionnaire Modified for Teens (PHQ-9M) [®]	Total score ≥10	89204-2
Patient Health Questionnaire-2 (PHQ-2) ^{®1}	Total score ≥3	55758-7
Beck Depression Inventory-Fast Screen (BDI-FS) ^{®1,2}	Total score ≥8	89208-3
Center for Epidemiologic Studies Depression Scale — Revised (CESD-R)	Total score ≥17	89205-9
Edinburgh Postnatal Depression Scale (EPDS)	Total score ≥10	99046-5
PROMIS Depression	Total score ≥60	71965-8
Instruments for Adults (18+ years)	Positive Finding	LOINC Code (Required for numerator 1)
Patient Health Questionnaire (PHQ-9) [®]	Total score ≥10	44261-6
Patient Health Questionnaire-2 (PHQ-2) ^{®1}	Total score ≥3	55758-7
Beck Depression Inventory-Fast Screen (BDI-FS) ^{®1,2}	Total score ≥8	89208-3
Beck Depression Inventory (BDI-II)	Total score ≥20	89209-1
Center for Epidemiologic Studies Depression Scale — Revised (CESD-R)	Total score ≥17	89205-9
PROMIS Emotional Distress Depression — Short Form	Total score ≥60	77861-3
Duke Anxiety-Depression Scale (DUKE-AD) ^{®2}	Total score ≥30	90853-3
Edinburgh Postnatal Depression Scale (EPDS)	Total score ≥10	99046-5
My Mood Monitor (M-3) [®]	Total score ≥5	71777-7

¹Brief screening instrument. All other instruments are full-length.

²Proprietary; may be cost or licensing requirement associated with use.

(continued)



(PND-E) Prenatal Depression Screening *(continued)*

Instruments for Adults (18+ years)	Positive Finding	LOINC Code (Required for numerator 1)
PROMIS Depression	Total score ≥ 60	71965-8
Clinically Useful Depression Outcome Scale (CUDOS)	Total score ≥ 31	90221-3

Tips

- Use age-appropriate screening instruments.
- If there is a positive screen resulting from a PHQ-2 score, documentation of a negative finding from a PHQ-9 performed on the same day qualifies as evidence of follow-up.
- Train staff on the importance of depression screenings and recognizing the risk factors for depression in pregnancy.
- Develop a workflow that includes utilizing a standardized instrument for depression screenings at every visit.
- Ask your provider relations representative about ways to submit data to the health plan directly from your EHR/EMR.
- Document follow-up on positive screen on or up to 30 days after the first positive screen.

Description	Codes*
Behavioral Health Encounter	CPT: 90791, 90792, 90832–90839, 90845–90849, 90853, 90865–90869, 90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493 HCPCS: G0155, G0176, G0177, G0409–G0411, G0511, G0512, H0002, H0004, H0031, H0034–H0037, H0039, H0040, H2000, H2001, H2010–H2020, S0201, S9480, S9484, S9485
Depression Case Management Encounter	CPT: 99366, 99492–99494 HCPCS: G0512, T1016, T1017, T2022, T2023
Outpatient, Telephone, E-Visit, or Virtual Check-In with a Diagnosis of Depression or other Behavioral Health Condition	CPT: 98960–98962, 98966–98968, 98970–98972, 98980, 98981, 99078, 99202–99205, 99211–99215, 99242–99245, 99341, 99342, 99344, 99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99421–99423, 99441–99443, 99457, 99458, 99483, G0071, G0463, G2010, G2012, G2250, G2252, T1015 ICD-10: Applicable code between F01.511–F94.7, O90.6, O99.340–O99.345
Exercise Counseling	ICD-10: Z71.82
Dispensed Antidepressant Medication	

Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow up (i.e., a negative screen) on the same day as a positive screen on a brief screening instrument.

*Codes subject to change.





(POD) Pharmacotherapy for Opioid Use Disorder

Measure evaluates the percentage of opioid use disorder (OUD) pharmacotherapy events that lasted at least 180 days among persons 16 years of age and older with a diagnosis of OUD and a new OUD pharmacotherapy event during the measurement period.

Measure must meet the following requirements:

- ✓ Persons 16 years of age and older.
- ✓ OUD dispensing event is captured between a 12-month period that begins on Jul. 1 of the year prior to the measurement period and ends on Jun. 30 of the measurement period (intake period).
- ✓ Persons must have a negative medication history (no OUD pharmacotherapy medications) as of 31 days prior to the new OUD pharmacotherapy.

Care Gap Closure: The measure is event-based, and it is met when the person adheres to OUD pharmacotherapy for 180 days or more without a gap in treatment of more than eight days.



Tips

- Closely monitor medication prescriptions and do not allow any gap in treatment of eight or more consecutive days.
- Offer mutual help like peer recovery support, harm reduction, 12-step fellowships such as Alcoholics Anonymous (AA) or Narcotics Anonymous (NA).
- Provide timely submission of claims with correct medication name, dosage, frequency, and days covered.
- Reach out proactively within 24 hours if the person does not keep scheduled appointment to schedule another.
- Inform person of the risks and benefits of pharmacotherapy, treatment without medication, and no treatment.

Note: Persons can have multiple treatment period start dates and treatment periods during the measurement period. Treatment periods can overlap.

Description	Codes*
Buprenorphine/Naloxone (Sublingual Tablet, Buccal Film, Sublingual Film)	HCPCS: J0572, J0573, J0574, J0575
Buprenorphine Oral, Implant, and Injectable**	HCPCS: H0033, J0570, J0571, Q9991, Q9992
Methadone	HCPCS: G2067, G2078, H0020, S0109
Naltrexone Injection	HCPCS: G2073, J2315

*Codes subject to change.

**Methadone is not included on the medication lists for this measure. Methadone for OUD administered or dispensed by federally certified opioid treatment programs (OTP) is billed on a medical claim. A pharmacy claim for methadone would be indicative of treatment for pain rather than OUD.





(SAA) Adherence to Antipsychotic Medications for Individuals With Schizophrenia

The index prescription start date (IPSD) is the earliest prescription dispensing data for any antipsychotic medication during the measurement period.

The treatment period is defined as the time beginning on the IPSD through the last day of the measurement period.

Measure evaluates the percentage of persons 18 years of age and older during the measurement period with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

If an oral medication and a long-acting injection are dispensed on the same day, calculate number of days covered by an antipsychotic medication using the prescription with the longest days' supply.



Tips

- Consider the use of long-acting injectable antipsychotic medications to increase adherence.
- Provide education on how to take the medication, expected side effects, and the importance of talking to the prescriber before stopping the medication.

Oral Antipsychotics				
• aripiprazole	• haloperidol	• molindone	• ziprasidone	• thioridazine
• asenapine	• iloperidone	• olanzapine	• chlorpromazine	• trifluoperazine
• brexpiprazole	• loxapine	• paliperidone	• fluphenazine	• amitriptyline-perphenazine
• cariprazine	• lumateperone	• quetiapine	• perphenazine	
• clozapine	• lurasidone	• risperidone	• prochlorperazine	• thiothixene

Long-Acting Injections	
Description	Prescription
Long-acting Injections 14-Day Supply	• risperidone (excluding Perseris®)
Long-acting Injections 28-Day Supply	• aripiprazole • aripiprazole lauroxil • fluphenazine decanoate • haloperidol decanoate • olanzapine
Long-acting Injections 30-Day Supply	• risperidone (Perseris®)
Long-acting Injections 35-Day supply	• paliperidone palmitate (Invega Sustenna)
Long-acting Injections 104-Day supply	• paliperidone palmitate (Invega Trinza)
Long-acting Injections 201-Day Supply	• paliperidone palmitate (Invega Hafyera)





(SMC) Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia

Measure evaluates the percentage of persons 18 to 64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease who had an LDL-C test during the measurement period.



Tips

- Provide persons/caregivers with lab orders for HbA1c or glucose lab test and cholesterol or LDL-C to be completed yearly.
- Educate the person and caregiver about the risks associated with taking antipsychotic medications and the importance of regular follow-up care.
- Consider using standing orders to get lab tests.
- Educate persons and their caregivers on the importance of completing annual visits and blood work.
- Discuss weight management options and encourage persons to increase physical activity, improve sleep, and maintain a well-balanced diet.
- Submit applicable codes.

Description	Codes*
LDL-C Lab Test	CPT: 80061, 83700, 83701, 83704, 83721

LDL-C Test Result or Finding	Codes*
Most Recent LDL-C Less Than 100 mg/dL (CAD) (DM)	CPT-CAT-II: 3048F
Most Recent LDL-C 100-129 mg/dL (CAD) (DM)	CPT-CAT-II: 3049F
Most Recent LDL-C Greater Than or Equal to 130 mg/dL (CAD) (DM)	CPT-CAT-II: 3050F

*Codes subject to change.





(SMD) Diabetes Monitoring for People With Diabetes and Schizophrenia

Measure evaluates the percentage of persons 18 to 64 years of age (as of the last day of the measurement period) with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C test and an HbA1c test during the measurement period.



Tips

- Provide persons/caregivers with lab orders for HbA1c or glucose lab test and cholesterol or LDL-C to be completed yearly.
- Educate the person and caregiver about the risks associated with taking antipsychotic medications and the importance of regular follow-up care.
- Consider using standing orders to get lab tests.
- Educate persons and their caregivers on the importance of completing annual visits and blood work.
- Discuss weight management options and encourage persons to increase physical activity, improve sleep, and maintain a well-balanced diet.
- Submit applicable codes.

Description	Codes*
Glucose Lab Test	CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
HbA1c Lab Test	CPT: 83036, 83037 LOINC: 17855-8, 17856-6, 4548-4, 4549-2, 96595-4
HbA1c Test Result or Finding	CAT II: 3044F, 3046F, 3051F, 3052F
LDL-C Lab Test	CPT: 80061, 83700, 83701, 83704, 83721 LOINC: 12773-8, 13457-7, 18261-8, 18262-6, 2089-1, 49132-4, 55440-2, 96259-7
LDL-C Test Result or Finding	CAT II: 3048F, 3049F, 3050F

*Codes subject to change.





(SSD) Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who are Using Antipsychotic Medications

Measure evaluates the percentage of persons 18 to 64 years of age with schizophrenia, schizoaffective disorder, or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement period.

Identify persons with diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder, and conduct a glucose or HbA1c lab test.



Tips

- Provide persons/caregivers with lab orders for HbA1c or glucose lab test to be completed yearly.
- Educate the person and caregiver about the risks associated with taking antipsychotic medications and the importance of regular follow-up care.
- Consider using standing orders to get lab tests.
- Educate persons and their caregivers on the importance of completing annual visits and blood work.
- Discuss weight management options and encourage persons to increase physical activity, improve sleep, and maintain a well-balanced diet.
- Submit applicable codes.

Description	Codes*
Glucose Lab Test	CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
HbA1c Lab Test	CPT: 83036, 83037
HbA1c Test Result or Finding	CPT II: 3044F, 3046F, 3051F, 3052F

*Codes subject to change.

Note: Do **not** include a modifier when using CPT II codes.





(UOP) Use of Opioids From Multiple Providers

Measure evaluates the percentage of persons 18 years and older receiving prescription opioids for ≥ 15 days during the measurement period who received opioids from multiple providers.

Three rates are reported:

- 1 Multiple Prescribers.** Identify all opioid medication dispensing events during the measurement period. Include persons who received opioids from four or more different prescribers during the measurement period. Use the NPI to determine if the prescriber for medication dispensing events was the same or different.
- 2 Multiple Pharmacies.** Identify all opioid medication dispensing events during the measurement period. Include persons who received opioids from four or more different pharmacies during the measurement period. Use the NPI to determine if the pharmacy for medication dispensing events was the same or different.
- 3 Multiple Prescribers and Multiple Pharmacies.** Identify all opioid medication dispensing events during the measurement period. Include persons who received opioids from four or more different prescribers and four or more different pharmacies during the measurement period (i.e., persons who are numerator compliant for both the Multiple prescribers and Multiple pharmacies rates).

Decreased score indicates improvement.



Tips

- Use the state Prescription Drug Monitoring Program (PDMP) database prior to initiating opioid therapy and periodically, ranging from every prescription to every three months.
- Educate persons on opioid safety and risk associated with long-term use and use of multiple opioids from different providers.

Opioid Medications Lists

- | | |
|--|---|
| <ul style="list-style-type: none"> • Acetaminophen Benzhydrocodone Medications List • Buprenorphine Medications List • Butorphanol Medications List • Acetaminophen Butalbital Caffeine Codeine Medications List • Acetaminophen Codeine Medications List • Aspirin Butalbital Caffeine Codeine Medications List • Aspirin Carisoprodol Codeine Medications List • Codeine Sulfate Medications List • Acetaminophen Caffeine Dihydrocodeine Medications List • Fentanyl Medications List • Acetaminophen Hydrocodone Medications List • Hydrocodone Medications List • Hydrocodone Ibuprofen Medications List • Hydromorphone Medications List • Levorphanol Medications List | <ul style="list-style-type: none"> • Meperidine Medications List • Methadone Medications List • Morphine Medications List • Belladonna Opium Medications List • Opium Medications List • Acetaminophen Oxycodone Medications List • Aspirin Oxycodone Medications List • Ibuprofen Oxycodone Medications List • Oxycodone Medications List • Oxymorphone Medications List • Naloxone Pentazocine Medications List • Tapentadol Medications List • Acetaminophen Tramadol Medications List • Tramadol Medications List |
|--|---|



